Native KCC2 interactome reveals PACSIN1 as a critical regulator of synaptic inhibition

Vivek Mahadevan‡*, C Sahara Khademullah††, Zahra Dargaei††, Jonah Chevrier†, Pavel Uvarov‡, Julian Kwan§, Richard D Bagshaw¶, Tony Pawson¶¶, Andrew Emili¶, Yves De Koninck§§, Victor Anggono¶¶, Matti Airaksinen‡, Melanie A Woodin*†

1Department of Cell and Systems Biology, University of Toronto, Toronto, Canada; 2Department of Anatomy, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 3Department of Molecular Genetics, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada; 4Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada; 5Institut Universitaire en Santé Mentale de Québec, Québec, Canada; 6Department of Psychiatry and Neuroscience, Université Laval, Québec, Canada; 7Queensland Brain Institute, Clem Jones Centre for Ageing Dementia Research, The University of Queensland, Brisbane, Australia

Abstract KCC2 is a neuron-specific K⁺-Cl⁻ cotransporter essential for establishing the Cl⁻ gradient required for hyperpolarizing inhibition in the central nervous system (CNS). KCC2 is highly localized to excitatory synapses where it regulates spine morphogenesis and AMPA receptor confinement. Aberrant KCC2 function contributes to human neurological disorders including epilepsy and neuropathic pain. Using functional proteomics, we identified the KCC2-interactome in the mouse brain to determine KCC2-protein interactions that regulate KCC2 function. Our analysis revealed that KCC2 interacts with diverse proteins, and its most predominant interactors play important roles in postsynaptic receptor recycling. The most abundant KCC2 interactor is a neuronal endocytic regulatory protein termed PACSIN1 (SYNDAPIN1). We verified the PACSIN1-KCC2 interaction biochemically and demonstrated that shRNA knockdown of PACSIN1 in hippocampal neurons increases KCC2 expression and hyperpolarizes the reversal potential for Cl⁻. Overall, our global native-KCC2 interactome and subsequent characterization revealed PACSIN1 as a novel and potent negative regulator of KCC2.

DOI: https://doi.org/10.7554/eLife.28270.001

Introduction

GABA and glycine are the key inhibitory neurotransmitters of the mature nervous system, and most synaptic inhibition is mediated by Cl⁻ permeable GABA_A and glycine receptors. This hyperpolarizing inhibition results from the inward gradient for Cl⁻ established primarily by the K⁺-Cl⁻ cotransporter KCC2, which exports Cl⁻ to maintain low intracellular Cl⁻ ([Cl⁻]_i) (Rivera et al., 1999; Doyon et al., 2016). KCC2 is a member of the nine-member family of cation-chloride cotransporters and is unique among the members because it is present exclusively in neurons of the CNS, and mediates the electroneutral outward cotransport of K⁺ and Cl⁻. KCC2 protein is encoded by the SLC12A5 gene, which via alternative splicing results in two transcript variants encoding the isoforms KCC2a and KCC2b (Payne et al., 1996; Uvarov et al., 2007).
During embryonic development, KCC2 expression is low and GABA and glycine act as excitatory neurotransmitters; however, during early postnatal development KCC2 expression is dramatically upregulated and GABA and glycine become inhibitory (Ben-Ari, 2002; Blaesse et al., 2009). Excitation-inhibition imbalance underlies numerous neurological disorders (Kahle et al., 2008; Nelson and Valakh, 2015), and in many of these disorders, the decrease in inhibition results from a reduction in KCC2 expression. In particular, KCC2 dysfunction contributes to the onset of seizures (Huberfeld et al., 2007; Kahle et al., 2014; Puskarjov et al., 2014; Stödberg et al., 2015; Saitsu et al., 2016), neuropathic pain (Coull et al., 2003), schizophrenia (Tao et al., 2012), and autism spectrum disorders (ASD) (Cellot and Cherubini, 2014; Tang et al., 2016a; Banerjee et al., 2016). Despite the critical importance of this transporter in maintaining inhibition and proper brain function, our understanding of KCC2 regulation is rudimentary.

In addition to its canonical role of Cl\(^{-}\) extrusion that regulates synaptic inhibition, KCC2 has also emerged as a key regulator of excitatory synaptic transmission. KCC2 is highly localized in the vicinity of excitatory synapses (Gulyás et al., 2001; Chamma et al., 2013) and regulates both the development of dendritic spine morphology (Li et al., 2007; Chevy et al., 2015; Llano et al., 2015) and function of AMPA-mediated glutamatergic synapses (Gauvain et al., 2011; Chevy et al., 2015; Llano et al., 2015). Thus, a dysregulation of these non-canonical KCC2 functions at excitatory synapses may also contribute to the onset of neurological disorders associated with excitation-inhibition imbalances.

KCC2 is regulated by multiple posttranslational mechanisms including phosphoregulation by distinct kinases and phosphatases (Lee et al., 2007; Kahle et al., 2013; Medina et al., 2014), lipid rafts and oligomerization (Blaesse et al., 2006; Watanabe et al., 2009), and protease-dependent cleavage (Puskarjov et al., 2012). KCC2 expression and function is also regulated by protein interactions,
including creatine kinase B (CKB) (Inoue et al., 2006), sodium/potassium ATPase subunit 2 (ATP1A2) (Ikeda et al., 2004), chloride cotransporter interacting protein 1 (CIP1) (Wenz et al., 2009), protein associated with Myc (PAM) (Garbarini and Delpire, 2008), 4.1N (Li et al., 2007), the glutamate receptor subunit GluK2, its auxiliary subunit Neto2 (Ivakine et al., 2013; Mahadevan et al., 2014; Pressey et al., 2017), coflin1 (CFL1) (Chevy et al., 2015; Llano et al., 2015), the GABA\(_\alpha\) receptor subunit GABA\(_\alpha\)R1 (Wright et al., 2017), metabotropic glutamate receptor subunits mGluR1/5 (Farr et al., 2004; Banke and Gegelashvili, 2008; Mahadevan and Woodin, 2016; Notartomo et al., 2017), and RAB11 (Roussa et al., 2016). However, since KCC2 exists in a large multi-protein complex (MPC) (Mahadevan et al., 2015), it is likely that these previously identified interactions do not represent all of the components of native-KCC2 MPCs.

In the present study, we performed unbiased affinity purifications (AP) of native-KCC2 coupled with high-resolution mass spectrometry (MS) using three different KCC2 epitopes from whole-brain membrane fractions prepared from developing and mature mouse brain. We found that native KCC2 exists in macromolecular complexes comprised of interacting partners from diverse classes of transmembrane and soluble proteins. Subsequent network analysis revealed numerous previously unknown native-KCC2 protein interactors related to receptor recycling and vesicular endocytosis functions. We characterized the highest-confidence KCC2 partner identified in this screen, PACSIN1, and determined that PACSIN1 is a novel and potent negative regulator of KCC2 expression and function.

**Results**

**Determining affinity purification (AP) conditions to extract native-KCC2**

In order to determine the composition of native KCC2 MPCs using AP-MS, we first determined the detergent-based conditions that preserve native KCC2 following membrane extraction. In a non-denaturing Blue-Native PAGE (BN-PAGE), native-KCC2 migrated between 400 kDa – 1000 kDa in the presence of the native detergents C\(_{12}\)E\(_9\) (nonaethylene glycol monododecyl ether), CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate) 1, and DDM (n-dodecyl \(\beta\)-d-maltoside). However, all other detergent compositions previously used for KCC2 solubilization resulted in KCC2 migration at lower molecular weights (Figure 1a). This indicates that native detergent extractions are efficient at preserving higher order KCC2 MPCs. Upon further analysis using standard SDS-PAGE, we observed that the total KCC2 extracted was greater in C\(_{12}\)E\(_9\) and CHAPS-based detergent extractions in comparison with all other detergents (Figure 1a, Figure 1—source data 1 and 2), hence we restricted our further analysis to C\(_{12}\)E\(_9\) and CHAPS-based membrane preparations.

To determine which of these two detergents was optimal for our subsequent full-scale proteomic analysis, we performed AP-MS to compare the efficacy of C\(_{12}\)E\(_9\) versus CHAPS-solubilized membrane fractions. Immunopurification was performed on membrane fractions prepared from adult (P50) wild-type (WT) mouse brain, using a well-validated commercially available C-terminal KCC2 antibody (Williams et al., 1999; Gulyás et al., 2001; Woo et al., 2002; Mahadevan et al., 2014) and a control IgG antibody. In both detergent conditions, we recovered maximum peptides corresponding to KCC2 from the KCC2 pull downs (KCC2-AP), in comparison to the control IgG pull downs (IgG-AP), confirming the specificity of the C-terminal KCC2 antibody (Figure 1b and Figure 1—source data 1). However, upon further examination, two key pieces of evidence indicated that C\(_{12}\)E\(_9\)-based conditions are optimal for proteomic analysis of native KCC2. First, we observed peptides corresponding to both KCC2 isoforms-a and -b; in C\(_{12}\)E\(_9\)-based samples, but we could only detect peptides corresponding to KCC2 isoform-a in KCC2-APs from CHAPS-based samples. Second, we observed a higher enrichment of peptides corresponding to previously identified KCC2 interactors belonging to the family of Na+/K+ ATPases (ATP1A1-3), and the family of creatine kinases (CKB, CKMT1), and coflin1 (CFL1) in the KCC2-AP from C\(_{12}\)E\(_9\)-based samples. Based on these results, we concluded that C\(_{12}\)E\(_9\)-based solubilization conditions yield more KCC2-specific binding partners and fewer IgG-specific binding partners compared to CHAPS, and thus provide a higher stringency for KCC2 AP-MS. Thus, we performed all subsequent proteomic analysis of native KCC2 on samples solubilized with C\(_{12}\)E\(_9\).
Figure 1. KCC2 multi-protein complexes can be extracted using native detergents. (a) BN-PAGE and SDS-PAGE separation of solubilized membrane fractions prepared from ~P50 mouse brain, using the detergents listed in the associated table. Protein separations were western-blotted and probed with antibodies indicated on the left. O, oligomer; M, monomer. Blots are representative of two independent biological replicates. (b) Comparison of the top 35 proteins identified with high confidence in C-terminal KCC2 antibody immunoprecipitations from CHAPS-based or C_{12}E_{9}-based membrane extractions. IgG-AP immunoprecipitations were performed as a control. Heat maps represent log scale spectral counts of individual proteins per condition, expressed relative to global spectral counts. Unique peptides corresponding to KCC2 (indicated in red font) were most abundant in both conditions, confirming the specificity of the C-terminal antibody. Previously identified KCC2 interacting partners are identified by asterisks. Proteins in green represent those that commonly co-precipitated with KCC2 regardless of the detergent extraction.

DOI: https://doi.org/10.7554/eLife.28270.003

Figure 1 continued on next page
Multi-epitope (ME) proteomic analysis of KCC2 complexes in the developing and mature brain

To focus our proteomic analysis on KCC2b, which is the abundant isoform primarily responsible for the shift from excitatory to inhibitory GABA during early postnatal development (Uvarov et al., 2007; Kaila et al., 2014), we used a multi-epitope approach that allowed us to distinguish the KCC2 isoforms (Figure 2a). The C-terminal antibody recognizes both isoforms (Uvarov et al., 2007; 2009), so we chose to use another antibody that is specifically raised against the unique N-terminal tail of the KCC2b isoform. Lastly, we used a phosphospecific antibody for serine 940 (pS940), as phosphorylation of this residue increases KCC2 surface expression and/or transporter function (Lee et al., 2007; Lee et al., 2011). We validated these three KCC2 antibodies (C-terminal, N-terminal, and pS940) for KCC2-immunoenrichment (Figure 2—figure supplement 1) (Mahadevan et al., 2014). Moreover, by taking a multi-epitope approach, we significantly increased the likelihood of detecting KCC2 interactions that may be missed during single-epitope AP approaches. We performed 34 rounds of AP-MS including both developing (P5) and mature/adult (P50) WT mouse brain lysates (Figure 2—source data 1). We could not use KCC2-knockout brains since these animals die at birth, so as an alternative we used a mock IP for each sample condition in the absence of the KCC2 antibody using parallel preimmunization immunoglobulin (IgG/IgY) as negative controls. We obtained 440 potential KCC2 protein interactors with 99% confidence and a 1% false discovery rate. We identified KCC2 peptides spanning the entire sequence of KCC2 with ~44% sequence coverage, primarily at the C- and N-terminal tails (Figure 2b); and in both the developing and mature brain, KCC2 peptides were the most abundant peptides identified in the KCC2-IPs (Figure 2c). While the KCC2 C-terminal antibody recovered peptides from both isoforms of KCC2, the N-terminal KCC2b-specific antibody did not recover any KCC2a isoform-specific peptides, indicating the specificity of the antibodies used, and the success of KCC2-immunoenrichment in our AP-assays.

The KCC2 interactome

To build the KCC2 interactome, all potential KCC2 protein interactors were filtered according to their spectral count enrichment in the KCC2-APs, and normalized to IgG IPs. In the first pass filter grouping, we included proteins with at least two unique peptides and peptide-spectrum matches and a 3-fold increase in KCC2 spectral counts in the KCC2-AP in comparison to IgG-AP (Figure 3—source data 1). This yielded ~75 putative-KCC2 partners. In the second pass filter grouping, we identified additional putative-KCC2 partners by including those with only one unique peptide, or less than three-fold KCC2-AP enrichment, if they met one of the following criteria: (a) the protein was a previously validated KCC2 physical/functional interactor; (b) the protein family already appeared in the first-pass filter; (c) the protein appeared as a single-peptide interactor across multiple experiments (e.g. multiple antibodies, or in lysates from both age timepoints, or in both replicates). Including these additional proteins from the second pass filtering yielded 186 putative-KCC2 partners. We next eliminated the 36 proteins that have been previously identified as commonly occurring spurious interactors in LC/MS experiments as indicated in the CRAPome database (Figure 3—source data 2) (Mellacheruvu et al., 2013). By applying these filtering criteria and processes, we established a total list of 150 putative KCC2 partners in our present LC-MS assay (Figure 3—source data 3). More than half of these KCC2 interactors were exclusively enriched in KCC2-APs from the mature brain (85 proteins, ~57% overlap), while approximately one-third (41 proteins, ~27% overlap) were identified across both the developing and mature brain (Figure 3—source data 3).
Figure 2. Multi-epitope AP identifies native-KCC2 protein constituents in mouse brain. (a) Schematic of the locations of anti-KCC2 antibodies. (b) The primary KCC2 amino acid sequence. Red indicates the protein coverage of KCC2 identified by MS analysis, yellow indicates unique coverage for KCC2a and KCC2b isoforms. MS/MS spectra of peptides unique for KCC2a and KCC2b. Right: the MS/MS ion fragmentation of the corresponding amino acid sequence is indicated above the spectra. (c) Spectral and peptide count plots of proteins in AP with all three anti-KCC2 antibodies in developing brain. Figure 2 continued on next page.
membrane fractions (P5, left) and adult brain membrane fractions (P50, right). Peptide and spectral counts are normalized (anti-KCC2/IgG) and plotted on a log scale. Red circles - highly enriched KCC2 bait. Blue circles - highly enriched PACSIN1 target peptides. Dark-grey circles - top proteins enriched with KCC2-AP in comparison to IgG control-AP. Light-grey circles - proteins enriched in IgG control-AP in comparison to KCC2-AP and known spurious interactors.

DOI: https://doi.org/10.7554/eLife.28270.007
The following source data and figure supplement are available for figure 2:

Source data 1. LC/MS replicates.
DOI: https://doi.org/10.7554/eLife.28270.009
Figure supplement 1. Validation of KCC2 antibodies for immunodepletion.
DOI: https://doi.org/10.7554/eLife.28270.008

Only relatively small percentages were exclusively enriched in the developing brain (24 proteins, ~16% overlap).

Next, we segregated the 150 putative KCC2 partners into high-confidence (platinum, gold), moderate-confidence (silver), or lower confidence (bronze) putative KCC2-interactors (Figure 3, Table 1 and Figure 3—source data 4). This segregation was based on the largest probability of a bait-prey pair across all replicate purifications, as indicated by the MaxP score (Choi et al., 2012), and the presence of a particular protein across replicates, and spectral enrichment of a particular protein across all experiments. Platinum KCC2-partners are those proteins enriched in a minimum of two out of three replicates, show 5+ fold spectral enrichment, and a MaxP SAINT score ≥ 0.89. Gold KCC2-partners were those proteins enriched in only one replicate with normalized spectral count enrichments ≥ 5 and a MaxP SAINT score ≥ 0.89. Silver KCC2-partners were those with normalized spectral count enrichments between 3 and 5, and a MaxP score between 0.7 and 0.89. Bronze KCC2-partners were all remaining proteins that were not designated as Platinum, Gold or Silver. Lastly, we added 31 proteins that have been previously established as KCC2-physical/functional partners but were not identified in our present LC-MS assay (Figure 3—source data 4). The proteins identified in the present screen (150) and the proteins previously established as key KCC2 physical/functional partners (31), together constitutes the 181 members of the proposed KCC2 interactome. All 181 proteins were included in subsequent network analyses.

Members of KCC2 interactome are highly represented at excitatory synapses

To interpret the potential functional role of KCC2-protein interactors, we first segregated them based on their abundance at excitatory and inhibitory synapses. To perform this analysis, we mapped the KCC2 interactome to the excitatory synapse-enriched postsynaptic density (PSD), Nlgn1, Lrrtm1, and Lrrtm2 proteomes (Collins et al., 2006; Loh et al., 2016), or the inhibitory synapse-enriched iPSD, GABA_{A}R, GABA_{B}R, NLGN2, Slitrk3, and GlyR proteomes (Heller et al., 2012; Del Pino et al., 2014; Kang et al., 2014; Loh et al., 2016; Nakamura et al., 2016; Schwenk et al., 2016; Uezu et al., 2016) (Figure 4—source data 1). Interactome mapping revealed that ~43% of proteins in the KCC2 interactome (77/181) were exclusively enriched at excitatory synapses, while only ~2% of proteins (4/181) were exclusively enriched at inhibitory synapses (Figure 4a,b). However, ~15% proteins (30/181) were mapped to both excitatory and inhibitory synapses, whereas ~39% proteins (70/181) did not map to either synapses.

To further examine the KCC2 interactome based on cellular functions, we performed an Ingenuity Pathway Analysis (IPA) to segregate the KCC2-interactors into highly enriched Gene Ontology (GO) classes. Performing this IPA analysis revealed that KCC2 partners segregate into multiple cellular and molecular functional nodes, which we then combined into three broad categories that collectively had high p values: ion homeostasis, dendritic cytoskeleton rearrangement, and receptor trafficking (Figure 4c-e; Figure 4—source data 2). KCC2 has been previously associated with both ion homeostasis and dendritic spine morphology, and consistent with this previous work we identified previously characterized KCC2 functional or physical interactors, including subunits of the sodium/potassium (Na\(^{+}/K\(^{-}\)) ATPase, including the previously characterized KCC2 interactor ATP1A2 (Ikeda et al., 2004), and Cofilin1, which was recently demonstrated to be important for KCC2-mediated plasticity at excitatory synapses (Chevy et al., 2015; Llano et al., 2015). The third category,
### Figure 3. ME-AP reveals distinct KCC2 constituents in developing and mature brain.

Summary of the top 70 proteins identified with high confidence across KCC2-ME AP in the developing and mature brain. **PLATINUM** interactors: proteins enriched in a minimum of 2/3 replicates, and show 5+ fold spectral enrichment. **GOLD** interactors: proteins with 5+ fold spectral enrichment in one replicate. **SILVER** interactors: 3–5 fold spectral enrichment; **BRONZE** interactors: 1.5–3 fold spectral enrichment. Enrichment is in KCC2-AP in comparison with IgG-AP. Heat map represents log scale spectral enrichment of individual proteins per antibody condition, relative to respective control conditions. See Table 1 for a list of the transmembrane and soluble KCC2 interactors.

**DOI:** https://doi.org/10.7554/eLife.28270.010

The following source data and figure supplements are available for figure 3:

**Source data 1.** All validated peptide-spectrum matches for KCC2-AP and IgG-AP.

**DOI:** https://doi.org/10.7554/eLife.28270.013

**Source data 2.** Top CRAPome members that appear at 50% frequency.

**DOI:** https://doi.org/10.7554/eLife.28270.014

**Figure 3 continued on next page**
receptor trafficking, has a denser network (clustering coefficient of 0.63 and an average of ~4.4 neighbors) in comparison to the other networks, suggesting a tight link between KCC2 and proteins in this node. Notably, this analysis revealed multiple novel putative-KCC2 partners, including PACSIN1, SNAP25, RAB11FIP5, CSNK2A1, DNMT1 and AP2B1. All these novel putative interactors have established functions in membrane recycling and/or trafficking of glutamate receptor subunits (Carroll et al., 1999; Lee et al., 2002; Vandenberghe et al., 2005; Pérez-Otaño et al., 2006; Selak et al., 2009; Sanz-Clemente et al., 2010; Anggono et al., 2013; Bacaj et al., 2015). In order to determine the spatiotemporal expression profiles of the KCC2 interactome, we first performed transcriptomic analysis and hierarchical clustering of high-resolution human brain RNAseq data (Kang et al., 2011; Willsey et al., 2013) (obtained from http://brain-map.org). We observed that SLC12A5 mRNA is expressed with several members of the receptor trafficking node in the hippocampus (Figure 5a), amygdala, thalamus, cerebellum and cortex (Figure 5—figure supplement 1; Figure 5—source data 1). The RNAseq data does not distinguish between isoforms KCC2a and KCC2b, which equally represented in the neonatal brain, while KCC2b is the predominant isoform in the adult brain.

In order to independently validate the utility of the KCC2 interactome, we proceeded to biochemical and functional analysis. We focused this validation analysis on proteins in the receptor trafficking category for two reasons: (i) the most abundant putative-KCC2 partner, PACSIN1 (PKC and CSNK2A1 substrate in neurons; also called as Syndapin1) is present in the receptor trafficking node; and (ii) the tightest KCC2-subnetwork exists in receptor trafficking node, indicating a dense interconnectivity between these proteins.

**PACSIN1 is a novel native-KCC2 binding partner**

To biochemically and functionally validate our KCC2 interactome, we chose to focus on the putative KCC2-PACSIN1 interaction. The rationale for this selection was based on the following: (1) PACSIN1 is the most abundant KCC2 interactor in our LC-MS assay (next only to KCC2), with a high normalized spectral count ratio and a high MaxP score, and with extensive amino acid sequence coverage (Figure 5—figure supplement 2); (2) PACSIN1 is a substrate for PKC, and PKC is a key regulator of KCC2 (Lee et al., 2007); (3) PACSIN1 is a substrate for CSNK2A1, and our LC-MS assay revealed CSNK2A1 also as a putative KCC2-interactor; (4) PACSIN1 is abundant at both excitatory and inhibitory synapses (Pérez-Otaño et al., 2006; Del Pino et al., 2014); and (5) PACSIN1 was identified as an abundant KCC2 interactor using two antibodies (N-terminal and pS940) in multiple replicates.

To independently verify whether KCC2 associated with PACSIN1, we performed a co-immunoprecipitation assays from adult whole brain native membrane preparations. We found that PACSIN1 was immunoprecipitated with an anti-KCC2b antibody, but not with control IgY antibodies (Figure 5b). Using a previously well-validated PACSIN1 antibody (Anggono et al., 2013), we confirmed this interaction in the reverse direction, indicating the existence of a KCC2-complex with PACSIN1 in vivo (Figure 5b). Consistent with our ability to co-immunoprecipitate KCC2 and PACSIN1, we found that the expression profiles of KCC2 and PACSIN1 are temporally aligned in the mouse brain (Figure 5c). To determine whether native-KCC2 complexes are stably associated with PACSIN1, we performed an antibody-shift assay coupled with two-dimensional BN-PAGE (2D BN-PAGE), which is a strategy that has been used previously to examine the native assemblies of several transmembrane protein multimeric complexes (Schwenk et al., 2010, 2012), including that of native-KCC2 (Mahadevan et al., 2014, 2015). Using this approach, we first verified that the addition
### Table 1. KCC2 protein partners identified by ME-APs

| Protein name | UniProt ID | Spectral ratio | MaxP | ES | IS | P5 | P50 | pS940 |
|--------------|------------|----------------|------|----|----|----|-----|-------|
| KCC2b        | Q91V14-2   | 349.0          | 1    | X  | X  | X  | X   | X     |
| KCC2a        | Q91V14-1   | 203.8          | 1    | X  | X  | X  | X   | X     |
| PACSIN1      | Q61644     | 136.0          | X    | X  | X  | X  | X   | X     |
| SLC4A1       | Q6X893     | 54.0           | 1    | X  |     |     |     |       |
| ATP2B4       | Q6Q477     | 44.0           | 1    | X  |     |     |     | X     |
| KIF21B       | Q9QXL1     | 41.0           | 1    |     |     |     |     | X     |
| VCP          | Q01853     | 24.0           | 1    | X  |     |     |     |       |
| GLS          | D3Z7P3     | 23.5           | 1    | X  |     |     |     |       |
| RAB11FIP5    | Q8R361     | 22.0           | 1    | X  |     | X  |     | X     |
| SRCIN1       | Q9QW66     | 17.0           | 1    |     |     | X  |     | X     |
| RNF8         | Q8VC56     | 16.0           | 1    |     |     |     |     | X     |
| JAGN1        | Q5XKN4     | 12.0           | 1    |     |     |     |     | X     |
| PPIA3        | P60489     | 11.0           | 1    |     |     |     | X   | X     |
| SLC2A1       | P17809     | 11.0           | 0.96 | X  |     |     |     |       |
| YWHAE        | P62259     | 10.0           | 0.99 | X  | X  | X  | X   | X     |
| ACTN4        | P57780     | 9.0            | 1    |     |     | X  |     |       |
| CRMP1        | P97427     | 8.0            | 1    | X  |     | X  |     | X     |
| PIP5NM2      | Q6ZPQ6     | 8.0            | 1    |     |     | X  |     |       |
| ACO2         | Q99K10     | 7.0            | 1    |     |     | X  |     | X     |
| COX4I1       | P19783     | 6.0            | 0.96 |     |     |     |     |       |
| SLC4A10      | Q5DTL9     | 6.0            | 1    | X  | X  |     |     |       |
| USP24        | B1AY13     | 6.0            | 1    |     |     |     |     | X     |
| YWHAG        | P61982     | 6.0            | 0.96 | X  | X  | X  | X   | X     |
| CT1QB        | P14106     | 5.0            | 0.89 |     |     | X  | X   |       |
| CCT6A        | P80317     | 5.0            | 0.99 |     |     | X  |     |       |
| CPSF6        | Q6NVF9     | 5.0            | 0.99 |     |     |     |     |       |
| DDX5         | Q61656     | 5.0            | 0.99 |     |     | X  |     |       |
| DYNC1L11     | Q8R1Q8     | 5.0            | 0.78 |     |     |     | X   |       |
| SEC23A       | Q01405     | 5.0            | 0.99 |     |     | X  |     | X     |
| SLC8A2       | Q8K596     | 5.0            | 0.99 |     |     | X  |     |       |
| TRIM3        | Q9R1R2     | 5.0            | 0.78 |     |     | X  |     | X     |
| CANX         | P35564     | 4.5            | 1    |     | X  | X  | X   | X     |
| ATP5H        | Q9DCX2     | 4.0            | 0.81 |     |     | X  |     |       |
| ATP6V1E1     | P50518     | 4.0            | 0.78 |     |     | X  |     |       |
| DDX17        | Q501J6     | 4.0            | 0.96 |     |     |     |     |       |
| DNAJA3       | Q99M87     | 4.0            | 0.78 |     |     | X  |     | X     |
| DPYSL3       | Q62188     | 4.0            | 0.96 |     |     |     |     |       |
| EWSR1        | Q61545     | 4.0            | 1    |     |     | X  | X   |       |
| MAG          | P20917     | 4.0            | 0.96 |     |     | X  | X   |       |
| MDH2         | P08249     | 4.0            | 0.96 |     |     | X  |     |       |
| RTCB         | Q99LF4     | 4.0            | 0.98 |     |     | X  |     |       |
| SNRPA        | Q62189     | 4.0            | 0.96 |     |     |     |     |       |
| STOML2       | Q99JB2     | 4.0            | 0.96 |     |     | X  |     |       |
| STRN3        | Q9ERG2     | 4.0            | 0.96 |     |     |     |     | X     |

Table 1 continued on next page
| Protein name | UniProt ID | Spectral ratio | MaxP | ES | IS | P5 | P50 | pS940 |
|--------------|------------|----------------|------|----|----|----|-----|-------|
| YWHAQ        | P68254     | 4.0            | 0.78 | X  |    | X  | X   |       |
| INA          | P46660     | 3.6            | 1    | X  |    | X  | X   |       |
| ATP6V1F      | Q9D1K2     | 3.5            | 0.95 |    | X  | X  | X   |       |
| DCTN2        | Q99KJ8     | 3.5            | 1    | X  | X  | X  | X   |       |
| CD47         | Q61735     | 3.2            | 0.9  |    | X  | X  | X   |       |
| ACOX3        | Q9EPL9     | 3.0            | 0.78 |    | X  | X  | X   |       |
| AP2B1        | Q9DBG3     | 3.0            | 1    | X  | X  | X  | X   |       |
| APBA1        | B2RUJ5     | 3.0            | 0.78 |    | X  | X  | X   |       |
| ATP2A2       | Q55143     | 3.0            | 0.81 | X  |    | X  | X   |       |
| CMPK1        | Q9DBP5     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| CRTC1        | Q68ED7     | 3.0            | 0.78 |    |    |    |    |       |
| CTNNA2       | Q61301     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| FLI1         | Q9JJJ28    | 3.0            | 0.78 | X  | X  | X  | X   |       |
| FXYD7        | P59648     | 3.0            | 0.78 |    | X  | X  | X   |       |
| GPM6A        | P35802     | 3.0            | 0.93 | X  |    | X  | X   |       |
| GRID2        | Q61625     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| NARS         | Q8BP47     | 3.0            | 0.78 |    | X  | X  | X   |       |
| NDUF2        | Q9CQ75     | 3.0            | 1    |    |    |    |    |       |
| NUDT21       | Q9CQF3     | 3.0            | 0.78 |    |    |    |    |       |
| PPP1CA       | P62137     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| PPP2CA       | P63330     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| PRR2         | E9PUL5     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| SFPQ         | Q8VIJ6     | 3.0            | 1    | X  | X  | X  | X   |       |
| SIRT2        | Q8VDQ8     | 3.0            | 0.89 |    | X  | X  | X   |       |
| SLC1A2       | P43006     | 3.0            | 0.69 | X  | X  | X  | X   |       |
| TCP1         | P11983     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| TRIO         | Q0KL02     | 3.0            | 0.78 | X  | X  | X  | X   |       |
| PTN          | P63089     | 2.7            | 1    |    | X  |    |    |       |
| RAB2A        | P53994     | 2.7            | 0.84 | X  |    | X  | X   |       |
| NDUF5S       | Q99LY9     | 2.5            | 0.82 |    |    |    |    |       |
| CCT2         | P80314     | 2.5            | 1    | X  | X  | X  | X   |       |
| DNM1         | P39053     | 2.5            | 1    | X  | X  | X  | X   |       |
| SLC25A11     | Q9CR62     | 2.5            | 0.93 | X  | X  | X  | X   |       |
| DDX1         | Q91VR5     | 2.4            | 0.89 | X  | X  | X  | X   |       |
| NEDD4L       | Q8CFI0     | 2.4            | 0.91 | X  | X  | X  | X   |       |
| SYNGR3       | Q8R191     | 2.4            | 1    | X  |    | X  | X   |       |
| DLD*         | O08749     | 2.3            | 0.44 | X  | X  | X  | X   |       |
| SNAP25       | P60879     | 2.3            | 0.65 | X  | X  | X  | X   |       |
| DDX3X        | Q62167     | 2.3            | 0.79 | X  | X  | X  | X   |       |
| CAMK2G       | Q923T9     | 2.3            | 1    | X  |    |    |    |       |
| FASN         | P19096     | 2.3            | 1    | X  | X  | X  | X   |       |
| PKM          | P52480     | 2.2            | 0.85 |    |    | X  |    |       |
| NDUFA9       | Q9DC69     | 2.1            | 0.96 | X  |    |    |    |       |
| BASP1        | Q91XV3     | 2.1            | 0.72 | X  | X  | X  | X   |       |

Table 1 continued on next page
| Protein name | UniProt ID | Spectral ratio | MaxP | ES | IS | P5 | P50 | pS940 |
|-------------|-----------|----------------|------|----|----|----|-----|-------|
| CKB         | Q04447    | 2.0            | 0.64 | X  |    | X  |     |       |
| COX6C       | Q9CPQ1    | 2.0            | 0.89 |    |    | X  |     |       |
| CSN2A1      | Q60737    | 2.0            | 0.84 | X  |    | X  | X   |       |
| DHX9*       | Q70133    | 2.0            | 0.44 |    |    | X  | X   |       |
| DPYS2       | O08553    | 2.0            | 0.97 | X  | X  | X  | X   |       |
| EDC4        | Q3UIB9    | 2.0            | 1    |    |    |    |     |       |
| FUS         | P56959    | 2.0            | 0.94 | X  |    | X  | X   | X     |
| KCNAB2      | P62482    | 2.0            | 0.92 | X  |    |    |     |       |
| NDUFA8      | Q9DCJ5    | 2.0            | 0.96 |    |    |    | X   |       |
| NDUFS8      | Q8K3J1    | 2.0            | 1    |    |    |    |     |       |
| PDIA6       | Q9228R    | 2.0            | 0.89 | X  |    | X  |     |       |
| SFXN3*      | Q91V61    | 2.0            | 0.44 |    |    |    |     |       |
| SLC25A22    | Q9D6M3    | 2.0            | 0.89 | X  |    | X  |     |       |
| STMN2       | P55821    | 2.0            | 1    |    |    |    |     |       |
| TNR         | Q8BY91    | 2.0            | 1    | X  | X  | X  |     |       |
| TUBB4B      | P68372    | 1.9            | 0.55 |    |    | X  | X   |       |
| ATP5C1      | Q91VR2    | 1.9            | 0.6  | X  |    |    |     |       |
| PPIA        | P17742    | 1.8            | 0.74 |    |    | X  |     |       |
| CKMT1       | P30275    | 1.8            | 0.86 | X  |    | X  | X   |       |
| COX5A       | P12787    | 1.8            | 0.54 |    |    |    |     |       |
| C1QC*       | Q02105    | 1.8            | 0.43 |    |    |    | X   | X     |
| NDUFS1      | Q91VD9    | 1.8            | 0.88 | X  | X  | X  |     |       |
| WWP1        | Q8BZZ3    | 1.8            | 0.88 |    |    |    |     |       |
| ATP5B       | P56480    | 1.7            | 0.38 | X  |    | X  | X   | X     |
| CCT5        | P80316    | 1.7            | 0.81 | X  |    | X  |     |       |
| DCLK1       | Q9JLM8    | 1.7            | 0.96 | X  | X  | X  |     |       |
| SLC25A3     | Q8VEM8    | 1.7            | 1    | X  | X  | X  |     |       |
| SERTBN1     | Q62261    | 1.7            | 0.7  |    |    | X  | X   |       |
| TUBB3       | Q9ERD7    | 1.6            | 0.73 |    |    | X  | X   |       |
| CAMK2D      | Q6PHZ2    | 1.6            | 0.82 |    |    | X  |     |       |
| ATP6V0A1    | Q9Z1G4    | 1.5            | 0.92 | X  |    |    |     |       |
| CFL1*       | P18760    | 1.5            | 0.44 |    |    | X  |     |       |
| ATP1A2*     | Q6PIE5    | 1.5            | 0.04 | X  |    | X  | X   |       |
| ADGRL2      | Q8JZZ7    | 1.5            | 0.89 | X  |    |    |     |       |
| BSN         | O88737    | 1.5            | 0.72 | X  |    |    |     |       |
| DBT         | P53395    | 1.5            | 0.86 | X  |    | X  | X   |       |
| GTF2I       | Q9ESZ8    | 1.5            | 0.89 |    |    |    |     |       |
| HELB        | Q6N6AF    | 1.5            | 0.89 |    |    |    |     |       |
| HK1         | P17710    | 1.5            | 0.89 | X  |    |    |     |       |
| HMCN2       | A2AJ76    | 1.5            | 0.89 |    |    |    |     |       |
| LGI3        | Q8K406    | 1.5            | 0.89 |    |    |    |     |       |
| PC          | Q05920    | 1.5            | 0.89 |    |    |    |     |       |
| RAB3IP      | Q68EF0    | 1.5            | 0.89 |    |    |    |     |       |
| UQCR11      | Q9CPX8    | 1.5            | 0.89 | X  |    |    |     |       |

Table 1 continued on next page
of N-terminal KCC2b antibodies could shift a proportion of native-KCC2 to higher molecular weights, in comparison to IgY control antibodies (Figure 5d). Next, we observed that this antibody-induced shift in native-KCC2b using N-terminal antibody also shifted a population of native-PACSIN1 to comparable higher molecular weights (Figure 5d). Collectively, these experiments establish native-PACSIN1 as a novel KCC2-binding partner in whole brain tissue. The PACSIN family of proteins contains three members that share ~90% amino acid identity (Modregger et al., 2000). PACSIN1 is neuron-specific and is broadly expressed across multiple brain regions; PACSIN2 is ubiquitous and is abundant in cerebellar Purkinje neurons (Anggono et al., 2013; Cembrowski et al., 2016), and PACSIN3 is restricted to muscle and heart (Modregger et al., 2000). To determine which members of the PACSIN family binds to KCC2, we transfected PACSIN constructs (Anggono et al., 2013), with myc-KCC2b in COS-7 cells and performed co-immunoprecipitation. We observed that KCC2 robustly associates with PACSIN1, weakly interacts with PACSIN2, and does not interact with PACSIN3 (Figure 5e). Mouse PACSIN1 contains a membrane-binding F-BAR domain (aa 1–325), a SH3 domain (aa 385–441) that binds to phosphorylated targets, and a VAR (variable) region (aa 326–384) (Kessels and Qualmann, 2004; 2015). To determine the PACSIN1 region that is required for KCC2 binding we repeated our co-immunoprecipitation assays in COS-7 cells, but this time we used previously characterized PACSIN1 deletion constructs (Anggono et al., 2013)(Figure 5f). We discovered that removing either the SH3 (lane 3) or the F-BAR region (lane 6) did not disrupt the KCC2:PACSIN1 interaction, indicating that they are not necessary for KCC2 binding. In an analogous result, neither the SH3 domain alone (lane 7) nor F-BAR domain alone (lane 2) could interact with KCC2. However, KCC2 robustly co-precipitated with

Table 1 continued

| Protein name | UniProt ID | Spectral ratio | MaxP | ES | IS | P5 | P50 | pS940 |
|--------------|------------|----------------|------|----|----|----|----|-------|
| ATP1A1       | Q8VD2N2    | 1.5            | 0.67 | X  | X  | X  | X  |       |
| ATP5O        | Q9DBB20    | 1.5            | 0.71 | X  | X  | X  | X  |       |
| NDUFA4       | O6242S     | 1.4            | 0.51 | X  | X  | X  | X  |       |
| ATP6V0D1     | P51853     | 1.4            | 0.53 | X  | X  | X  | X  |       |
| ACAT1*       | O8QZT1     | 1.4            | 0.43 | X  | X  | X  | X  |       |
| ATP2B2*      | Q9ROK7     | 1.4            | 0.47 | X  | X  | X  | X  |       |
| TUBB4A       | O9DB6F9    | 1.4            | 0.64 | X  | X  | X  | X  |       |
| GNB1         | P62874     | 1.4            | 0.58 | X  | X  | X  | X  |       |
| C1QA         | PO8086     | 1.4            | 0.36 | X  | X  | X  | X  |       |
| NDUFA10      | Q9ELC3     | 1.4            | 0.65 | X  | X  | X  | X  |       |
| RAP2B*       | P61226     | 1.3            | 0.42 | X  | X  | X  | X  |       |
| SYT1         | P46096     | 1.3            | 0.65 | X  | X  | X  | X  |       |
| SLC1A3       | P56564     | 1.3            | 0.9  | X  | X  | X  | X  |       |
| CAPRIN1      | Q60865     | 1.3            | 0.56 | X  | X  | X  | X  |       |
| YWHAZ*       | P63101     | 1.3            | 0.44 | X  | X  | X  | X  |       |
| ATP1B3*      | Q6PC6      | 1.3            | 0.4  | X  | X  | X  | X  |       |
| STX1B*       | P61264     | 1.3            | 0.45 | X  | X  | X  | X  |       |
| NEFM         | P08553     | 1.2            | 0.78 | X  | X  | X  | X  |       |
| DLST         | Q9D2G2     | 1.2            | 0.72 | X  | X  | X  | X  |       |

Orange-Transmembrane.
Grey-Soluble.
Green-Secreted/Extracellular.
ES – excitatory synapse.
IS – inhibitory synapse.
DOI: https://doi.org/10.7554/eLife.28270.017
Figure 4. Members of the KCC2 interactome are highly represented at excitatory synapses. The KCC2 interactome mapped to (a) the excitatory synapse-enriched proteomes or, (b) the inhibitory synapse-enriched proteomes. The thickness of the black radial lines in the foreground denotes the number of spectral enrichment (KCC2/IgG) in the log scale. Grey radial lines in the background denotes the previously identified physical/co-expression

IPA cellular function | P-value | IPA cellular function | P-value | IPA cellular function | P-value
--- | --- | --- | --- | --- | ---
Homeostasis of ion | 4.14E-12 | Organization of cytoskeleton | 4.09E-14 | Transport of vesicles | 9.66E-09
Transport of inorganic cation | 1.3E-11 | Microtubule dynamics | 3.27E-13 | Receptor-mediated endocytosis | 1.58E-07
Homeostasis of K+ | 6.37E-07 | Dendritic growth/branching | 1.03E-11 | Clathrin mediated endocytosis | 1.87E-07
Homeostasis of Na+ | 1.46E-05 | Morphology of dendritic spines | 7.22E-08 | Endocytosis of vesicles | 1.97E-06

KCC2 Interactome mapped exclusively at excitatory synapse
KCC2 Interactome mapped exclusively at inhibitory synapse
KCC2 Interactome mapped at both synapses
KCC2 Interactome unmapped at either synapses

Clustering coefficient | Average # of neighbors
--- | ---
a | b | c
0.425 | 3.2
0.63 | 3.3
0.63 | 4.4
PACSIN1 when the VAR region alone was co-expressed with KCC2 (lane 5), indicating that the VAR region is sufficient to mediate the KCC2 interaction.

**PACSIN1 is a negative regulator of KCC2 expression and function in hippocampal neurons**

KCC2 dysregulation has emerged as a key mechanism underlying several brain disorders including seizures (Fiunelli et al., 2013; Stödberg et al., 2015; Saitsu et al., 2016), neuropathic pain (Coull et al., 2003), schizophrenia (Tao et al., 2012), and autism spectrum disorders (ASD) (Cellot and Cherubini, 2014; Tang et al., 2016a). However, there are currently no existing KCC2 enhancers approved for clinical use, and thus there is a critical need to identify novel targets for the development of KCC2 enhancers. To determine whether PACSIN1 may be a potential target for regulating KCC2 function, we assayed for KCC2 function following PACSIN1 knockdown. We chose to assay for the canonical KCC2 function of Cl⁻ extrusion, as the loss of Cl⁻ homeostasis and thus synaptic inhibition, is causal for several neurological disorders (Coull et al., 2003; Huberfeld et al., 2007; Tao et al., 2012; Cellot and Cherubini, 2014; Toda et al., 2014; Kahle et al., 2014; Puskarjov et al., 2014; Stödberg et al., 2015; Banerjee et al., 2016; Saitsu et al., 2016; Tang et al., 2016b).

We assayed KCC2-mediated Cl⁻ extrusion by performing patch clamp recordings of the reversal potential for GABA (E_{GABA}), which is principally determined by |Cl⁻| (Kaila, 1994). Whole-cell patch clamp recordings were obtained from cultured hippocampal neurons that endogenously express KCC2. E_{GABA} was determined from current–voltage (IV) curves that were created by eliciting inhibitory postsynaptic currents (IPSCs), by puffing GABA (20 μM) at the soma while progressively step-depolarizing the postsynaptic holding potential (through current injection via the whole-cell patch pipette). A linear regression of the IPSC amplitude was used to calculate the voltage dependence of IPSCs; the intercept of this line with the abscissa was taken as E_{GABA} (mV), and the slope of this line as GABA conductance (pS). KCC2 function is best determined when the transporter is driven to extrude Cl⁻, which we achieved by loading the intracellular compartment with Cl⁻ via the whole-cell patch pipette (Doyon et al., 2016).

To determine whether PACSIN1 regulates KCC2-mediated Cl⁻ transport, we virally transduced neurons with plasmids containing a previously validated PACSIN1 shRNA to knockdown PACSIN1 (Anggono et al., 2013), or a scrambled shRNA, which served as the control recordings. Neurons were transduced at 5–7 days in vitro (DIV) and all the recordings were performed at 11–14 DIV. Neurons were selected for recording based on the presence of reporter fluorescence (~60% of neurons were transduced). When neurons expressed the PACSIN1 silencing shRNA, E_{GABA} was significantly hyperpolarized compared to control neurons expressing the scrambled shRNA (Figure 6a,b; control shRNA: –28.62 ± 3.07 mV, n = 9; PACSIN1 shRNA: –37.86 ± 1.73 mV, n = 11; t(18)=2.744, p=0.013). We found no significant change in the GABA_{R} conductance (Figure 6a,c; control shRNA: 6.93 ± 1.32 pS, n = 9; PACSIN1 shRNA: 12.96 ± 2.71 pS, n = 11; t(18)=1.86, p=0.079), which indicates that the effect is on Cl⁻ transport and not GABA conductance. In addition, we found no significant change in the resting membrane potential (RMP) (Figure 6d; control shRNA: –63.41 ± 1.48 mV, n = 11; PACSIN1 shRNA: –62.77 ± 2.21 mV, n = 9; t(18)=0.246, p=0.808), which indicates the change in the driving force for Cl⁻ was due to a change in E_{GABA} and not RMP. Together, these data...
Figure 5. Characterization of the PACSIN1-KCC2 interaction. (a) Spatiotemporal expression patterns of SLC12A5 and members of receptor trafficking node of the KCC2 interactome in the human brain; RNAseq data were analyzed in hippocampus. Pcw, postconceptual weeks. (b) Native KCC2 complexes from C12E9-solubilized whole-brain membrane fractions immunoprecipitated with IgY or anti-N-term KCC2 (left) and IgG or anti-PACSIN1 (right), and immunoblotted with antibodies as indicated. (c) Western blot analysis of developmental expression patterns of KCC2 and PACSIN1. (d) Figure 5 continued on next page

Mahadevan et al. eLife 2017;6:e28270. DOI: https://doi.org/10.7554/eLife.28270
indicate that knocking down PACSIN1 increases KCC2-mediated Cl⁻ transporter, which results in hyperpolarized $E_{\text{GABA}}$.

The electrophysiology experiments performed above using Cl⁻ loading through the patch pipette are important to test KCC2 function under an ionic load (Doyon et al., 2016). To determine the impact of PACSIN1 on KCC2 function under resting conditions, we repeated the electrophysiology recordings performed above to determine $E_{\text{GABA}}$, but this time, we used the gramicidin-perforated patch clamp technique to maintain the neuronal Cl⁻ gradient (Kyrozis and Reichling, 1995). Similar to our recordings above, we found a significant hyperpolarizing shift in $E_{\text{GABA}}$ in neurons expressing PACSIN1 shRNA versus control cells expressing scrambled shRNA (Figure 6e; control shRNA: $-46.93 \pm 2.78$ mV, $n = 7$; PACSIN1 shRNA: $-72.70 \pm 4.70$ mV, $n = 6$; $t(11)=4.9115$, $p=0.0005$). Taken together, our whole-cell and gramicidin-perforated patch clamp recordings reveal that knocking down KCC2 in cultured hippocampal neurons leads to a hyperpolarization of $E_{\text{GABA}}$ that strengthens inhibition, which results from an increase in KCC2-mediated Cl⁻ extrusion.

Due to the known role of PACSIN1 as an endocytic regulatory protein (Anggono et al., 2006; 2013; Pérez-Otaño et al., 2006; Del Pino et al., 2014; Widagdo et al., 2016), we hypothesized that PACSIN1 negatively regulates KCC2 function by altering its expression in the surface membrane. To test our hypothesis, we performed immunofluorescent staining of endogenous KCC2 in cultured hippocampal neurons transduced with PACSIN1 shRNA or scrambled shRNA (control cells). We observed a significant increase in KCC2 fluorescence in neurons expressing PACSIN1 shRNA in comparison with controls (Figure 6e; control shRNA: $58.86 \pm 2.53$ A.U., $n = 32$; PACSIN1 shRNA: $74.05 \pm 2.53$ A.U., $n = 32$; $t(31)=5.272$, $p<0.0001$). Taken together, our electrophysiological recordings and immunofluorescence results demonstrate that a reduction in PACSIN1 results in increased KCC2 expression and an increase in the strength of inhibition (hyperpolarization of $E_{\text{GABA}}$).

If PACSIN1 is a bona fide negative regulator of KCC2 expression, then overexpressing PACSIN1 should produce a reduction in KCC2 expression. To test this prediction, we again performed immunofluorescent staining of endogenous KCC2 in cultured hippocampal neurons transduced with either eGFP (control) or PACSIN1-eGFP. We observed a remarkable loss of KCC2 immunofluorescence when PACSIN1 was overexpressed in comparison to control eGFP (Figure 6f; control eGFP: $62.1 \pm 2.7$ A.U., $n = 23$; PACSIN1-eGFP: $11.31 \pm 3.17$ A.U., $n = 16$; $t(37)=12.13$, $p<0.0001$), which supports the conclusion that PACSIN1 negatively regulates KCC2 expression.

Discussion
We determined that the mouse brain KCC2 functional interactome is comprised of 181 proteins; and by mapping the KCC2 interactome to excitatory and inhibitory synapse proteomes and performing ingenuity pathway analysis, we determined that KCC2 partners are highly enriched at excitatory synapses and form a dense network with proteins involved in receptor trafficking. We validated the
Figure 6. PACSIN1 is a negative regulator of KCC2 expression and function. (a) Example IV curves measuring $E_{\text{GABA}}$ using Cl$^-$-loading through whole-cell configuration from cultured hippocampal neurons. Neurons were transduced with either control shRNA (n = 9; left) or PACSIN1 shRNA (n = 11; right). Summary of (b) $E_{\text{GABA}}$, (c) synaptic conductance, and (d) RMP from all experiments similar to the examples in a. (e) Summary of $E_{\text{GABA}}$ recordings obtained by gramicidin-perforated patch clamp recordings. (f) Example confocal microscopic immunofluorescent images from cultured hippocampal neurons transduced with control shRNA (n = 32) or PACSIN1 shRNA (n = 32) and stained with anti-KCC2 (red; scale bar, 10 μm); green immunostain reports transfection. Below: summary of fluorescence intensities. (g) Similar to f, except neurons were transduced with either control eGFP (n = 23) or PACSIN1-eGFP (n = 16). n values for all experiments on cultured neurons were obtained from a minimum of three independent sets of cultures. Statistical significance was determined using student’s t-tests (two-tailed); *p<0.05, ***p<0.001. For all summary plots, the error bars denote mean ± sem. The following figure supplements is available for Figure 6.

DOI: https://doi.org/10.7554/eLife.28270.026

Figure 6 continued on next page
utility of the KCC2-interactome that we presented, by verifying the biochemical interaction between PACSIN1 and KCC2, and by demonstrating that PACSIN1 participates in regulation of the level of expression of KCC2. Functional validation of the KCC2-PACSIN1 interaction revealed that PACSIN1 robustly and negatively regulates KCC2 expression.

While ion channels and GPCRs are known to predominantly exist in large multi-protein complexes in the CNS (Husi et al., 2000; Berkefeld et al., 2006; Collins et al., 2006; Müller et al., 2010; Schwenk et al., 2010; 2012; 2014; 2016; Nakamura et al., 2016; Pin and Bettler, 2016), similar studies on CNS solute carrier proteins (transporters) are still in their infancy (César-Razquin et al., 2015b; Comstra et al., 2017; Haase et al., 2017). Based on the critical importance of SLC transporters as therapeutic targets in both rare and common diseases (César-Razquin et al., 2015a; Lin et al., 2015), including that of KCC2 in human neurological diseases (Blaesse et al., 2009; Medina et al., 2014), our present study also fills a general gap in the field of CNS transporter proteomics.

A common caveat of isoform-counting in shot-gun proteomic experiments such as ours, is the problem of protein inference (Nesvizhskii and Aebersold, 2005). While we were able to discriminate KCC2 isoforms-a and -b, based on the presence of their unique peptides in their N-terminus (Figure 1c), it is not possible to categorize the remaining peptides to either isoform a or b due to their extensive shared homology. Therefore, targeted proteomics such as selected-reaction monitoring would be required to accurately establish the abundances of KCC2 isoforms. We report that native-detergents C12E9 and CHAPS extract KCC2 isoforms differentially (Figure 1b). We also report that native-detergents C12E9 and CHAPS pull-down different subsets of proteins along with some common interactors (Figure 1b). It is intriguing to note that there were several putative KCC2-partners uniquely identified with CHAPS (SLC44A1, ATP2B4, RNF8, JAGN1, CD47, SLC2A1 (Figure 1b). Although we did not perform exhaustive proteomics with CHAPS-based KCC2 extractions, because of the presence of these high-confidence proteins in the CHAPS-based KCC2 LC/MS, we did include these proteins in the KCC2-interactome. This demonstrates that detergent stabilities of KCC2 protein complexes are distinct, in line with other recent ion channel proteomic studies (Müller et al., 2010; Schulte et al., 2011; Schwenk et al., 2012).

Our KCC2 LC/MS identified previously established KCC2 proteins interactors, including ATP1A2 (Ikeda et al., 2004), CFL1 (Chevy et al., 2015; Llano et al., 2015), and CKB (Inoue et al., 2004; 2006), which add confidence to the validity of this interactome. We were initially surprised at the absence of other previously established KCC2 interactors, including: Neto2 (Ivaine et al., 2013; Mahadevan et al., 2015), GluK2 (Mahadevan et al., 2014; Pressey et al., 2017), 4.1N (Li et al., 2007), beta-pix (Chevy et al., 2015; Llano et al., 2015), RCC1 (Garbarini and Delpire, 2008), or signaling molecules PKC (Lee et al., 2007), WNK, SPAK and OSR (Friedel et al., 2015). The absence of these previously identified interactors may be due to any of the following caveats, which have been well recognized in previous ion channel and GPCR proteomic studies: (1) these interactions may be weak, transient, mediated by posttranslational modifications (Schulte et al., 2011), or mediated by intermediary partners; (2) these interactions are under-represented in the whole brain membrane fractions because they are restricted to specific brain regions; (3) antibody-epitope binding blocked endogenous interactions; (4) despite using the C12E9-based solubilization strategy that is known to stabilize ion pumps and transporters (Romero, 2009; Babu et al., 2010; Ramachandran et al., 2013) particular interactions may be better preserved by other detergent conditions.

Single particle tracking of surface KCC2 has revealed that ~ 66% of KCC2 is located synaptically (Chamma et al., 2012, 2013). While the density of surface KCC2 was not reportedly different between excitatory and inhibitory synapses, KCC2 was shown to dwell longer at excitatory synapses. Our observation that KCC2 interacting proteins are primarily enriched at excitatory synapses in comparison to inhibitory synapses is in line with this increased confinement of KCC2 at excitatory synapses.
synapses. The presence of KCC2 at excitatory synapses raises some interesting questions: How does KCC2–mediated Cl− extrusion regulate hyperpolarizing inhibition if it is preferentially localized near excitatory synapses? Why are the KCC2 partners exclusive to the inhibitory synapses, less represented when compared with excitatory synapses? One potential answer to both these questions is that: because of the difficulty in identifying components of inhibitory synapses, our knowledge of the proteins present at these structures is incomplete. Despite the fact that our network mapping incorporated 444 proteins known to be enriched at inhibitory synapses (Heller et al., 2012; Del Pino et al., 2014; Kang et al., 2014; Loh et al., 2016; Nakamura et al., 2016; Schwenk et al., 2016; Uezu et al., 2016), it is possible that we identified a smaller representation of inhibitory synapse-specific KCC2 partners in our present study. In this context, it is interesting to note that KCC2 itself was not identified in any of the above inhibitory synapse-enriched proteomes, and we assigned KCC2 as a member of the inhibitory synapse during network analyses, because of its established function at this locus. Another possibility is that KCC2 ‘moon-lights’ between inhibitory and excitatory synapses, as previously suggested (Blaesse and Schmidt, 2015). Our interactome supports this hypothesis as we identified 29 proteins (excluding KCC2) that are enriched at both synapses. However, future studies are required to systematically examine whether the KCC2 complexes containing these putative moon-lighting proteins are similar or distinct complexes within these loci. While the notion that excitatory and inhibitory synapses are distinct structures is widely accepted, emerging evidence from cortex suggests this may not be strictly true (Chiu et al., 2013; Higley, 2014). Under circumstances where excitatory and inhibitory synapses are in close physical proximity, the molecular complex involving KCC2 and these moonlighting proteins are ideally placed to execute cell-intrinsic E/I balance regulation, a hypothesis stemming from our present study that requires rigorous experimental testing.

Ever since the first discovery that KCC2 participates in the regulation of dendritic spine structures (Li et al., 2007), several studies have demonstrated 4.1N as a critical mediator of this non-canonical transporter-independent KCC2 function (Horn et al., 2010; Gauvain et al., 2011; Chamma et al., 2013; Fiumelli et al., 2013). Recently however, additional molecular players underlying this phenomenon, including COFL1, and ARHGEF7 (Beta-pix) have been identified to interact with KCC2 (Chevy et al., 2015; Llano et al., 2015). In the present study, we identify diverse high confidence (Platinum, Gold) cytoskeletal organizers belonging to distinct protein families such as CRMPs, 14-3-3 isoforms, SRCIN1, VCP, KIF21B, previously unsuspected to mediate KCC2-dependant non-canonical function. However, the precise relation between KCC2-dependant non-canonical functions and these putative partners in not currently known.

PACSIN1 is a well-established endocytic adapter protein that regulates the surface expression of distinct glutamate (Anggono et al., 2006, 2013; Pérez-Otario et al., 2006; Widagdo et al., 2016) and glycine receptors (Del Pino et al., 2014). We reveal PACSIN1 as a novel negative regulator of KCC2 expression in hippocampal neurons. We previously reported that native-KCC2 assembles as a hetero-oligomer that migrates predominantly above ~400 kDa (Mahadevan et al., 2014; 2015). Similar to KCC2, native-PACSIN1 also migrates above ~400 kDa (Kessels and Qualmann, 2006). Here, we report that while SLC12A5 and PACSIN1 mRNA transcripts increase in parallel in multiple brain regions throughout development, PACSIN1 overexpression remarkably decreases total KCC2 abundance. How does PACSIN1 exist in a stable complex with KCC2 when it negatively regulates KCC2 expression? Since KCC2 and PACSIN1 are both dynamically regulated by phosphorylation and PKC (Anggono et al., 2006; Lee et al., 2007; Clayton et al., 2009; Kahle et al., 2013), we predict that upon KCC2 phosphorylation, PACSIN1 uncouples from KCC2 rendering it incapable of negatively regulating KCC2. Numerous pathological situations are associated with decreased KCC2 phosphorylation at Ser940 (Wake et al., 2007; Lee et al., 2011; Sarkar et al., 2011; Toda et al., 2014; Ford et al., 2015; Mahadevan et al., 2015; Silayeva et al., 2015; Leonzino et al., 2016; Mahadevan and Woodin, 2016), resulting in decreased transporter expression and/or function. It will be important to determine whether any of these neurological deficits stem from PACSIN1-mediated decreases in KCC2. In the present study, we demonstrate that PACSIN1 shRNA increases KCC2 expression and strengthens inhibition, indicating that PACSIN1 is a target for intervention to upregulate KCC2 during pathological states.

In conclusion, the KCC2 interactome as presented here, serves as a molecular framework for systematically exploring how KCC2 up and down states can be dynamically regulated by its native...
molecular constituents, thereby providing a blueprint for subsequent detailed functional investigations.

Materials and methods

Animals and approvals

All experiments were performed in accordance with guidelines and approvals from the University of Toronto Animal Care Committee and the Canadian Council on Animal Care (University of Toronto Protocol #20012022). Animals of both sexes from wild-type mice, C57/Bl6 strain (Charles River Laboratories) were used throughout. Animals were housed in the Faculty of Arts and Science Biosciences Facility (BSF) in a 12 hr light: 12 hr d cycle, with 2–5 animals/cage.

Detergents

All biochemical preparations and centrifugations were performed at 4°C as previously described (Ivakine et al., 2013; Mahadevan et al., 2014, 2015). Systematic analysis of detergent solubility, and migration of native-KCC2 from crude membrane fractions were performed according to the workflow described in Figure 1—figure supplement 1. The following eight detergents (or detergent combinations) were used to solubilize whole brain membranes: C12E9 (1.5%; nonaethylene glycol monododecyl ether, Sigma-Aldrich, St. Louis, MO, #P9641), CHAPS (1.5%; 3-(3-Cholamidopropyl)dimethylammonio)-1-propanesulfonate hydrate, Sigma-Aldrich #C3023), DDM, (1.5%; DDM, n-dodecyl β-d-maltoside, Sigma-Aldrich #D4641), DOC (1%; sodium deoxycholate, Sigma-Aldrich #D6750), NP40 (1%; nonyl phenoxypolyethoxylethanol, Thermo Fisher Scientific # 28324), Triton-X-100 (1%; 4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol, t-Octylphenoxypolyethoxyethanol, Polyethylene glycol tert-octylphenyl ether, Sigma-Aldrich #X-100), SDS (0.1%; Sodium dodecyl sulphate, Sigma-Aldrich #71725) +DOC (1%), +NP40 0.5%.

Purification of KCC2 and in vivo co-immunoprecipitation

Mice (~P5, P50) were sacrificed, and brains were removed and homogenized on ice in PBS using a glass-Teflon homogenizer, followed by brief low-speed centrifugation. Soft-pellets were re-suspended in ice-cold lysis buffer [Tris-HCl, 50 mM, pH 7.4; EDTA, 1 mM; protease and phosphatase inhibitor mixture (Roche)], homogenized, and centrifuged for 30 min at 25,000 × g. Membrane pellets were re-suspended in solubilization buffer (4Xw/v) [Tris-HCl, 50 mM, pH 7.4; NaCl, 150 mM; EDTA, 0.05 mM; selected detergent(s), and protease and phosphatase inhibitor mixture(Roche)], solubilized for 3 hr on a rotating platform at 4°C, and centrifuged for 1 hr at 25,000 × g. For KCC2 and control co-immunoprecipitations, 20–100 µl GammaBind IgG beads were incubated on a rotating platform for 4 hr at 4°C in cold 1X PBS:

- mouse polyclonal C-term KCC2 antibody, Neuromab #N1/12, RRID AB_10697875;
- rabbit polyclonal C-term KCC2 antibody, Millipore, Temecula, CA, #07–432, RRID AB_310611;
- rabbit monoclonal pS940 KCC2, Phosphosolutions #p1551-940, RRID AB_2492213;
- chicken polyclonal N-term KCC2b antibody (Markkanen et al., 2014);
- IgG/IgY control antibodies

Following antibody binding, 20 mM DMP (dimethyl pimelimidate, ThermoFisher 21667) in cold 1X PBS was used to crosslink antibodies with the beads, according to manufacturer’s instructions. The crosslinking reaction was stopped by adding 50 mM Tris-HCl to quench excess DMP, and the antibody-conjugated beads were thoroughly washed with the IP buffer. 1–10 mg of pre-cleared mouse brain membrane fractions were incubated with KCC2 or control antibody-conjugated beads on a rotating platform for 4 hr at 4°C. After co-immunoprecipitation, the appropriate unbound fraction was saved for comparison with an equal amount of protein to calculate the IP-efficiency (Figure 2—figure supplement 1). The beads were washed twice with IP buffer containing detergent, and twice with IP-buffer excluding the detergent. The last wash was performed in 50 mM ammonium bicarbonate. Co-immunoprecipitation experiments for validating KCC2 and PACSIN1 was performed similar to the above procedure, in the absence of DMP-crosslinking. In a subset of validation experiments, anti-PACSIN1 antibody (Synaptic Systems #196002, RRID AB_2161839), was used for reverse co-IP. The break-down of LC/MS replicates are as follows:
• Optimization of LC/MS (Figure 1) using CHAPS and C12E9-solubilized membrane fractions were performed each with parallel IgG. (6XCHAPS KCC2) + (6XCHAPS IgG) + (2XC12E9 KCC2) + (2XC12E9 IgG)=16 AP/MS using 5 μg C-terminal pan-KCC2 antibody, and 1 mg of P50 membranes.

• LC/MS (Figures 2 and 3) using separate C12E9-solubilized membrane fractions (distinct from the lysates used for optimization experiments) were performed (with parallel IgG/IgY) as follows: (1XP50, C-term KCC2) + (1XP50, pS940 KCC2) + (1XP50, IgG) + (1XP50, N-term KCC2b) + (1XP50, IgY) + (1XP5, C-term KCC2) + (1XP5, IgG) + (1XP5, N-term KCC2b) + (1XP5, IgY)=9 AP/MS using 100 μg control/KCC2 antibody, and 10 mg of membrane, constitute the second biological replicate.

• The 25 AP/MS described above constitute the primary data presented in this manuscript. In addition, the 9 AP/MS experiments corresponding to (Figures 2 and 3) were repeated again using a separate batch of P5 and P50 lysates distinct from previous replicates, and using 1 mg membrane and 20 μg of Control/KCC2 antibodies, and this constitute the third biological replicate. Presence or absence of a protein across replicates is presented in Figure 3—source data 3.

Mass spectrometry

Mass spectrometry for the creation of the KCC2 interactome (Figures 2 and 3) was performed at the SPARC Biocentre at SickKids Research Institute (Toronto, Ontario). Mass spectrometry for the determination of optimal detergents for native KCC2 extraction (Figure 1) was performed in the lab of Dr. Tony Pawson at the Lunenfeld-Tanenbaum Research Institute (LTRI), Mount Sinai Hospital (Toronto, ON) and in the CBTC (University of Toronto). Details on the individual experiments performed in each facility is located in Figure 2—source data 1.

For all MS experiments, proteins were eluted from beads by treatment with double the bead volume of 0.5 M ammonium hydroxide (pH 11.0), and bead removal by centrifugation; this procedure was repeated 2x. The combined supernatants were dried under vacuum, reduced with DTT, and the free cysteines were alkylated with iodoacetamide. The protein concentration was measured, and trypsin was added at a ratio of 1:50; digestion occurred overnight at 37˚C. The peptides were purified by C18 reverse phase chromatography on a ZipTip (Millipore, Bellerica, MA). Specifics of the MS in the three facilities are below:

SPARC

Orbitrap analyzer (Q-Exactive, ThermoFisher, San Jose, CA) outfitted with a nanospray source and EASY-nLC nano-LC system (ThermoFisher, San Jose, CA). Lyophilized peptide mixtures were dissolved in 0.1% formic acid and loaded onto a 75 μm x 50 cm PepMax RSLC EASY-Spray column filled with 2 μM C18 beads (ThermoFisher San, Jose CA) at a pressure of 800 Bar. Peptides were eluted over 60 min at a rate of 250 nl/min using a 0% to 35% acetonitrile gradient in 0.1% formic acid. Peptides were introduced by nanoelectrospray into the Q-Exactive mass spectrometer (Thermo-Fisher). The instrument method consisted of one MS full scan (400–1500 m/z) in the Orbitrap mass analyzer with an automatic gain control target of 1e6, maximum ion injection time of 120 ms and a resolution of 70,000 followed by 10 data dependent MS/MS scans with a resolution of 17,500, an AGC target of 1e6, maximum ion time of 120 ms, and one microscan. The intensity threshold to trigger a MS/MS scan was set to 1.7e4. Fragmentation occurred in the HCD trap with normalized collision energy set to 27. The dynamic exclusion was applied using a setting of 10 s.

CBTC

The peptides were analyzed on a linear ion trap-Orbitrap hybrid analyzer (LTQ-Orbitrap, ThermoFisher, San Jose, CA) outfitted with a nanospray source and EASY-nLC split-free nano-LC system (ThermoFisher, San Jose, CA). Lyophilized peptide mixtures were dissolved in 0.1% formic acid and loaded onto a 75 μm x 50 cm PepMax RSLC EASY-Spray column filled with 2 μM C18 beads (ThermoFisher San, Jose CA) at a pressure of 800 BAR. Peptides were eluted over 60 min at a rate of 250 nl/min using a 0% to 35% acetonitrile gradient in 0.1% formic acid. Peptides were introduced by nano electrospray into an LTQ-Orbitrap hybrid mass spectrometer (Thermo-Fisher). The instrument method consisted of one MS full scan (400–1500 m/z) in the Orbitrap mass analyzer, an automatic
gain control target of 500,000 with a maximum ion injection of 200 ms, one microscan, and a resolution of 120,000. Ten data-dependent MS/MS scans were performed in the linear ion trap using the ten most intense ions at 35% normalized collision energy. The MS and MS/MS scans were obtained in parallel fashion. In MS/MS mode, automatic gain control targets were 10,000 with a maximum ion injection time of 100 ms. A minimum ion intensity of 1000 was required to trigger an MS/MS spectrum. The dynamic exclusion was applied using a maximum exclusion list of 500 with one repeat count with a repeat duration of 15 s and exclusion duration of 45 s.

LTRI
Nano-LCMS using a home-packed 0.75 μm x 10 cm C18 emitter tip (Reprosil-Pur 120 C18-AQ, 3 μm). A Nano LC-Ultra HPLC system (Eksigent) was coupled to an LTQ Orbitrap Elite (ThermoFisher) and samples were analyzed in data-dependent acquisition mode. A 60000 resolution MS scan was followed by 10 CID MS/MS ion trap scans on multiply charged precursor ions with a dynamic exclusion of 20 s. The LC gradient was delivered at 200 nl/minute and consisted of a ramp of 2–35% acetonitrile (0.1% formic acid) over 90 min, 35–80% acetonitrile (0.1% formic acid) over 5 min, 80% acetonitrile (0.1% formic acid) for 5 min, and then 2% acetonitrile for 20 min.

Analysis of mass spectra and protein identification
All MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, San Jose, CA, USA; version 1.4.0.288) and X! Tandem (The GPM, thegpm.org; version CYCLONE (2010.12.01.1)). Sequest was set up to search Uniprot-mus +musculus_reviewed_Oct172015.fasta (unknown version, 25231 entries) assuming the digestion enzyme trypsin. X! Tandem was set up to search the Uniprot-mus +musculus_reviewed_Oct172015 database (25248 entries) also assuming trypsin. Sequest and X! Tandem were searched with a fragment ion mass tolerance of 0.020 Da and a parent ion tolerance of 10.0 PPM. Carbamidomethyl of cysteine was specified in Sequest and X! Tandem as a fixed modification. Deamidation of asparagine and glutamine and oxidation of methionine were specified in Sequest as variable modifications. Glu->pyro Glu of the n-terminus, ammonia-loss of the n-terminus, gln->pyro Glu of the n-terminus, deamidated of asparagine and glutamine and oxidation of methionine were specified in X! Tandem as variable modifications.

Scaffold (version Scaffold_4.7.2, Proteome Software Inc., Portland, OR) was used to validate MS/MS-based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability. Peptide Probabilities from X! Tandem were assigned by the Peptide Prophet algorithm (Keller et al., 2002) with Scaffold delta-mass correction. Peptide probabilities from Sequest were assigned by the Scaffold Local FDR algorithm. Protein identifications were accepted if they could be established at greater than 95.0% probability and contained at least one identified peptide. Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins were annotated with GO terms from gene_association.goa_uniprot (downloaded Dec 14, 2015) (Ashburner et al., 2000).

In addition, peak lists obtained from MS/MS spectra were identified independently using OMSSA version 2.1.9 (Geer et al., 2004), X!Tandem version X! Tandem Sledgehammer (2013.09.01.1) (Craig and Beavis, 2004), Andromeda version 1.5.3.4 (Cox et al., 2011), MS Amanda version 1.0.0.5242 (Dorfer et al., 2014), MS-GF +version Beta (v10282) (Kim and Pevzner, 2014), Comet version 2015.02.rev. 3 (Eng et al., 2013), MyriMatch version 2.2.140 (Tabb et al., 2007) and Tide (Diamant and Noble, 2011). The search was conducted using SearchGUI version 2.2.2 (Vaudel et al., 2011).

Protein identification was conducted against a concatenated target/decoy version (Elias and Gygi, 2010) of the Mus musculus (24797,>99.9%), Sus scrofa (1,<0.1%) complement of the UniProtKB (Apweiler et al., 2004) (version of December 2015, 24798, Mus Musculus) canonical and isoform sequences). The decoy sequences were created by reversing the target sequences in SearchGUI. The identification settings were as follows: Tryptsin with a maximum of two missed cleavages; 10.0 ppm as MS1 and 0.5 Da as MS2 tolerances; fixed modifications: Carbamidomethylation of C (+57.021464 Da), variable modifications: Deamidation of N (+0.984016 Da), Deamidation of Q (+0.984016 Da), Oxidation of M (+15.994915 Da), Pyrolidone from E (−18.010565 Da), Pyrolidone
Peptides and proteins were inferred from the spectrum identification results using PeptideShaker version 1.9.0 (Vaudel et al., 2015). Peptide Spectrum Matches (PSMs), peptides and proteins were validated at a 1.0% False Discovery Rate (FDR) estimated using the decoy-hit distribution. Spectrum counting abundance indexes were estimated using the Normalized Spectrum Abundance Factor (Powell et al., 2004) adapted for better handling of protein inference issues and peptide detectability. While the two independent protein algorithm searches largely matched with each other, a small subset of proteins were identified with high confidence using the SearchGUI/Peptideshaker platforms that were not identified with the ThermoFisher Scientific/Scaffold platforms.

The mass spectrometry data along with the identification results have been deposited to the ProteomeXchange Consortium (Vizcaíno et al., 2014) via the PRIDE partner repository (Martens et al., 2005) at https://www.ebi.ac.uk/pride/archive/ with the dataset identifier PXD006046.

**Dataset filtering**

Protein candidates from replicate LC/MS screens were subject to the following criteria to build the KCC2 interactome. First pass filter grouping: at least two unique peptides and fold change of total spectra above 1.5. Second pass filter grouping: for proteins with only one unique peptide, consider whether (a) the protein isoform is an already validated KCC2 interactor in literature; (b) the protein isoform already appears in the first pass filter; (c) the protein isoform appears as a single-peptide interactor across experiments (using the same epitope KCC2 IPs/different epitope KCC2 IPs/different developmental time KCC2 IPs). If a particular protein isoform matches any of the above criteria, it gets shifted to the first pass filter grouping. Finally, the proteins that appear in the KCC2 interactome that are previously identified spurious interactors as identified in the CRAPome database (Mellacheruvu et al., 2013) were further eliminated. For the existing proteins, a MaxP-SAINt score (Choi et al., 2012) was assigned and proteins were grouped as Platinum, Gold, Silver or Bronze interactors prior to subsequent PPI (protein-protein interaction) network analysis. See Figure 3—figure supplement 3 for a detailed description of the path towards constructing the KCC2 interactome.

**Integrated PPI network analysis and data representation**

Protein interactions were integrated with curated, high-throughput and predicted interactions from I2D ver. 2.3 database (Brown and Jurisica, 2007), FpClass high-confidence predictions (Kotlyar et al., 2015) and from the BioGRID database (Stark et al., 2006). Networks were visualized using Cytoscape ver. 3.3.0 (Shannon et al., 2003; Cline et al., 2007). Components of the KCC2 interactome were mapped to the excitatory synapse-enriched PSD, Nlgn1, Lrrtm1 and Lrrtm2 proteomes (Collins et al., 2006; Loh et al., 2016), or the inhibitory synapse-enriched GABA_A_R, GABA_B_R, Nlg2, Slitrk3 and GlyR proteomes (Heller et al., 2012; Del Pino et al., 2014; Kang et al., 2014; Loh et al., 2016; Nakamura et al., 2016; Schwenk et al., 2016; Uezu et al., 2016). In the PPI networks, the thickness of the black radial lines in the foreground denotes the number of spectral enrichment (KCC2/IgG) in the log scale ranging from 2.13 for the highly enriched interactor to 0.08 for the least enriched interactor. For representing the previously established KCC2 physical/functional interactors not identified in this study, an arbitrary value of 0.05 was used for indicating the thickness of black radial lines (See Figure 4—source data 1). Grey radial lines in the PPI network background denotes the previously identified physical/co-expression networks across all interactome members as identified from BioGRID and FpClass databases. Venn diagrams were made using Venny, online tool (http://bioinfogp.ub.es/tools/venny/); heat maps were made using Morpheus online tool provided by the Broad Institute (https://software.broadinstitute.org/morpheus/).

**In vitro co-immunoprecipitation**

HEK-293 and COS7 cells obtained from the ATCC were authenticated using Short Tandem Repeat (STR) profiling and checked for mycoplasma contamination. For co-immunoprecipitation experiments, cells were transfected with KCC2b-MYC, eGFP control, eGFP-PAC3IN1/2/3, or eGFP-PAC3IN1-deletion constructs (0.25 μg/construct) using Lipofectamine (Invitrogen) at 70% confluence. Thirty-six hours after transfection, cells were washed with ice-cold 1 x PBS and lysed in modified...
BN-PAGE analysis and antibody-shift assay

Native-membrane fractions were prepared similarly as described (Swamy et al., 2006; Schwenk et al., 2012; Mahadevan et al., 2014; 2015). Antibody-shift assay and 2D BN-PAGE analysis of native-KCC2 complexes were performed as described previously (Mahadevan et al., 2014; 2015). Briefly, 50 μg - 100 μg of C12E5 solubilized complexes were pre-incubated for 1 hr with 10 μg of anti-N-terminal KCC2b antibody or chicken IgY whole molecule, prior to the addition of Coomassie blue G250. 1D-BN-PAGE was performed as described above using home-made 4% and 5% bistris gels as described (Swamy et al., 2006). After the completion of the gel run, excised BN-PAGE lanes were equilibrated in Laemmli buffer containing SDS and DTT for 15 min at room temperature to denature the native proteins. After a brief rinse in SDS-PAGE running buffer, the excised BN-PAGE lanes were placed on a 6% or 8% SDS-PAGE gel for separation in the second dimension. After standard electro-blotting of SDS-PAGE-resolved samples on nitrocellulose membrane, the blot was cut into two molecular weight ranges; the top blots were subjected to western blotting analysis with Rb anti-KCC2, and the bottom blots with Rb anti-PACSIN1. Antibody-shift experiments (Figure 5d) using hippocampal membranes are representative from two independent biological replicates.

PACSIN overexpression and shRNA constructs

All PACSIN constructs used for overexpression and shRNA constructs have been previously validated for specificity (Anggono et al., 2013; Widagdo et al., 2016). The PACSIN1 shRNA-targeting sequence (sh#1, 5’-GGCCAGCTCATCGAGAAA-3’) or control shRNA sequence was inserted into the pSuper vector system (Oligoengine) as described previously (Anggono et al., 2013). The efficiency and specificity of the PACSIN1 and control shRNA constructs were tested in HEK 293 T cells overexpressing GFP-PACSIN1, and they were subsequently cloned into pAAV-U6 for lentiviral production (serotype AAV2/9).

Cultured hippocampal neurons and electrophysiology

Low-density cultures of dissociated mouse hippocampal neurons were prepared as previously described (Acton et al., 2012; Mahadevan et al., 2014). Electrophysiological recordings were performed using pipettes made from glass capillaries (World Precision Instruments, Sarasota, FL), as previously described (Acton et al., 2012; Mahadevan et al., 2014). Neuronal transduction with viral vectors was performed at DIV 5–7 and the recordings were performed at DIV 11–14. For Cl− loading experiments in whole-cell configuration, pipettes (5–7 MΩ) were filled with an internal solution containing the following (in mM): 110 K+-gluconate, 30 KC1, 10 HEPES, 0.2 EGTA, 4 ATP, 0.3 GTP, and 13 phosphocreatine (pH 7.4 with KOH, 300 mOsm). For gramicidin-perforated recordings, pipettes were filled with an internal solution containing the following (in mM): 130 K+-gluconate, 10 KC1, 10 HEPES, 0.2 EGTA, 4 ATP, 0.3 GTP, 13 phosphocreatine, and 50 μg/ml gramicidin (pH 7.4 with KOH, 300 mOsm). Cultured neurons were continuously perfused (at ~1 mL/min) with standard extracellular solution containing: 150 NaCl, 3 KC1, 3 CaCl2·2H2O, 2 MgCl2·6H2O, 10 HEPES, and 5 glucose (pH 7.4 with NaOH, 300 mOsm). Cultured neurons were selected for electrophysiology based on the following criteria: (1) a healthy oval or pyramidal-shaped cell body; (2) multiple clearly identifiable processes; (3) a cell body and proximal dendrites that were relatively isolated; and (4) reporter fluorescence (if applicable). Recordings started when the series resistance dropped below 50 MΩ. Recordings were amplified with an Axon Instruments Multiclamp 700B and digitized using an Axon...
Instruments Digidata 1322a (Molecular Devices; Sunnyvale, CA). To determine the reversal potential for GABA ($E_{\text{GABA}}$), neurons were held at $-60$ mV under whole-cell voltage clamp and the membrane potential was stepped in $+10$ mV increments from $-80$ to $-40$ mV (this holding potential was set through current injection via the whole-cell patch pipette). During each membrane potential step, a 20 μM GABA puff was applied onto the soma using a picospritzer (Parker, Hollis, NH, USA). The IPSC amplitude represents the maximum current measured during the recordings performed for the $E_{\text{GABA}}$ measurement. Using Clampfit (version 9.2; Molecular Devices; Sunnyvale, CA, USA), two cursors were placed on the recording trace (one just before the current, and the other at the peak of the current), and the peak amplitude was exported to Prism (version 5.01) and graphed against the holding potential. A linear regression of the IPSP amplitude versus membrane/holding potential was achieved using Prism and the intercept of this line with the abscissa was taken as $E_{\text{GABA}}$, and the slope of this line was taken as the synaptic conductance. For resting membrane potential, a whole-cell patch clamp was achieved, the amplifier was set to $I = 0$, and the corresponding potential was measured under current clamp mode. Electrophysiological values have not been corrected for the liquid junction potential of $\sim 7$ mV.

Fixed immunostaining and confocal microscopy

DIV 12–14 cultured hippocampal neurons were first rinsed with 1X PBS, and fixed in 4% paraformaldehyde for 10 min on ice followed by washing thrice with 1X PBS. Neurons were then permeabilized with 1X PBS containing 10% goat serum and 0.5% Triton X-100 for 30 min, followed by a 45 min incubation with rabbit anti-KCC2 (Millipore 07–432) antibodies at 37°C to detect endogenous proteins. Finally, neurons were washed thrice with 1X PBS and incubated with Alexa-fluor 555-conjugated goat anti-rabbit antibody for 45 min at 37°C. Neurons were imaged on a Leica TCS SP8 confocal system with a Leica DMI 6000 inverted microscope (Quorum Technologies). Cultured neurons were selected for immunostaining based on the following criteria: (1) with a healthy oval or pyramidal-shaped cell body; (2) multiple clearly identifiable processes; (3) a cell body and proximal dendrites that were relatively isolated; (4) reporter fluorescence (if applicable). Images were acquired using 3D Image Analysis software (Perkin Elmer). Images were obtained using a 63 x 1.4 NA oil immersion objective. Imaging experiments were performed and analyzed in a blinded manner. Using ImageJ, four bisecting lines were drawn across the center of the cell (Figure 6—figure supplement 1). The peak values of each line (2 values/line) were used to calculate peak fluorescent intensity of KCC2 at the membrane. Fluorescence intensity is plotted in arbitrary units (a.u.).

Statistics

For electrophysiology and immunostaining data (Figure 6), ‘n’ values report the number of neurons, and were obtained from a minimum of three independent sets of cultured neurons (produced from different litters). Example recordings in Figure 6a are representative of n = 9 (shRNA control) and n = 11 (PACSIN1 shRNA). Example recordings in Figure 6e are representative of n = 32 (shRNA control) and n = 32 (PACSIN1 shRNA). Example recordings in Figure 6f are representative of n = 23 (eGFP) and n = 16 (PACSIN1-eGFP). Data in Figure 6b,c,e and f are mean ± SEM. Statistical significance was determined using either SigmaStat or GraphPad Prism (version 5.01) software. Statistical significance in Figure 6b,c,d,e and f was determined using Student’s t-tests (two-tailed); all data sets passed the normal distribution assumptions test. Statistical significance is noted as follows: *p<0.05, **p<0.01, ***p<0.001. Exact p and t values are reported in the Results text.

Figures 1a, 5b, c and d are representative of two independent biological replicates. Figure 5f is representative of three independent biological replicates. Figure 5e is representative of four independent biological replicates.

Acknowledgements

We thank the following persons for technical assistance with LC/MS: Dr. Suzanne Ackloo at the Centre for Biological Timing and Cognition, University of Toronto; Drs. Paul Taylor and Jonathan Krieger, at the SPARC BioCentre, Hospital for Sick Children. We thank Dr. Karen Colwill at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital for coordinating data sharing and LC-MS analyses from experiments conducted at the LTRI facility. We thank EMBL-EBI/Wellcome Trust Proteomics Bioinformatics workshop, Drs. Harald Barsnes and Marc Vaudel, University of
Bergen, for assistance with the PeptideShaker/CompOmics applications. This study was funded by the following: Simons Foundation Autism Research Initiative to MW and YDK; CIHR training grant from the Sleep and Biological Rhythms Training Program, Toronto to VM; The Academy of Finland grants to P.U. and MSA; The John T. Reid Charitable Trusts and Australian Research Council (ARC) project grant (DP170102402) to VA; CIHR foundation grant FRN-133431 to AE; CIHR Operating Grant to MW.

Additional information

**Funding**

| Funder                        | Author                          |
|-------------------------------|---------------------------------|
| Canadian Institutes of Health Research | Vivek Mahadevan                  |
|                               | Andrew Emili                     |
|                               | Melanie A Woodin                 |
| Simons Foundation             | Yves De Koninck                  |
|                               | Melanie A Woodin                 |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**

Vivek Mahadevan, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review and editing: C Sahara Khademullah, Zahra Dargaei, Jonah Chevrier, Julian Kwan, Richard D Bagshaw, Investigation, Methodology; Pavel Uvarov, Resources, Validation, Investigation, Methodology; Tony Pawson, Matti Airaksinen, Resources, Supervision, Methodology; Andrew Emili, Resources, Software, Supervision, Methodology; Yves De Koninck, Supervision, Funding acquisition; Victor Anggono, Resources, Methodology; Melanie A Woodin, Conceptualization, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing

**Author ORCIDs**

Vivek Mahadevan, [http://orcid.org/0000-0002-0805-827X](http://orcid.org/0000-0002-0805-827X)
Pavel Uvarov, [http://orcid.org/0000-0001-8439-6150](http://orcid.org/0000-0001-8439-6150)
Victor Anggono, [http://orcid.org/0000-0002-4062-4884](http://orcid.org/0000-0002-4062-4884)
Melanie A Woodin, [https://orcid.org/0000-0003-2984-8630](https://orcid.org/0000-0003-2984-8630)

**Ethics**

Animal experimentation: All experiments were performed in accordance with guidelines and approvals from the University of Toronto Animal Care Committee and the Canadian Council on Animal Care (University of Toronto Protocol #20012022). Animals of both sexes from wild-type mice, C57/Bl6 strain (Charles River Laboratories) were used throughout. Animals were housed in the Faculty of Arts and Science Biosciences Facility (BSF) in a 12h light: 12h d cycle, with 2-5 animals/cage.

**Decision letter and Author response**

Decision letter [https://doi.org/10.7554/eLife.28270.031](https://doi.org/10.7554/eLife.28270.031)
Author response [https://doi.org/10.7554/eLife.28270.032](https://doi.org/10.7554/eLife.28270.032)

**Additional files**

**Supplementary files**

- Transparent reporting form
  DOI: [https://doi.org/10.7554/eLife.28270.028](https://doi.org/10.7554/eLife.28270.028)

**Major datasets**

The following dataset was generated:
References

Acton BA, Mahadevan V, Mercado A, Uvarov P, Ding Y, Pressey J, Airaksinen MS, Mount DB, Woodin MA, a WM. 2012. Hyperpolarizing GABAergic transmission requires the KCC2 C-terminal iso domain. Journal of Neuroscience 32:8746–8751. DOI: https://doi.org/10.1523/JNEUROSCI.6089-11.2012, PMID: 22723714

Anggono V, Koç-Schmitz Y, Widagdo J, Kormann J, Quan A, Chen CM, Robinson PJ, Choi SY, Linden DJ, Plomann M, Huganir RL. 2013. PICK1 interacts with PACSIN to regulate AMPA receptor internalization and cerebellar long-term depression. PNAS 110:13976–13981. DOI: https://doi.org/10.1073/pnas.1312467110, PMID: 23918399

Anggono V, Smillie KJ, Graham ME, Valova VA, Cousin MA, Robinson PJ. 2006. Syndapin I is the phosphorylation-regulated dynamin partner in synaptic vesicle endocytosis. Nature Neuroscience 9:752–760. DOI: https://doi.org/10.1038/nn1695, PMID: 16648848

Anon . 2011. BrainSpan: Atlas of the Developing Human Brain.

Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O’Donovan C, Redaschi N, Yeh LS, Ch W, L-sl Y. 2004. UniProt: the universal protein knowledgebase. Nucleic Acids Research 32:115D–119. DOI: https://doi.org/10.1093/nar/gkh131, PMID: 14681372

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matesec JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000. Gene ontology: tool for the unification of biology. the gene ontology consortium. PNAS 97:20728–20732. DOI: https://doi.org/10.1073/pnas.97.22.12569, PMID: 11003537

Babu M, Greenblatt JF, Emili A, Strynadka NC, Reithmeier RA, Moraes TF. 2010. Structure of a SLC26 anion transporter STAS domain in complex with acyl carrier protein: implications for E. coli YchM in fatty acid metabolism. Structure 18:1450–1462. DOI: https://doi.org/10.1016/j.str.2010.08.015, PMID: 21070944

Bacaj T, Ahmad M, Jurado S, Malenka RC, Sidhu C, Schneider K, Smith MA, Soderling TR, Wilson SH, Wyszynski PK, Yajnik S, Xiang Z, Yassour M, Zavialov A, Zhou X, Zon LI, Zuckerman E, Zuckerman J, Zuberi S, Zhu X, Zvelebil M, Zhulin IB, Zvelebil M, Zhulin IB. 2008. The human protein reference database: new features and tools in the HPRD 2008 update. Nucleic Acids Research 36:1292–1301. DOI: https://doi.org/10.1093/nar/gkn659, PMID: 18254778

Banerjee A, Rikhye RV, Breton-Provencher V, Tang X, Li C, Li K, Runyan CA, Fu Z, Jaenisch R, Sur M. 2016. Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome. PNAS 113:E7287–E7296. DOI: https://doi.org/10.1073/pnas.1615330113, PMID: 27803317

Banke TG, Gogolashvili HG. 2008. Tonic activation of group I mGlur5 modulates inhibitory synaptic strength by regulating KCC2 activity. The Journal of Physiology 586:4925–4934. DOI: https://doi.org/10.1113/jphysiol.2008.157024, PMID: 18772206

Ben-Ari Y. 2002. Excitatory actions of gaba during development: the nature of the nurture. Nature Reviews Neuroscience 3:728–739. DOI: https://doi.org/10.1038/nrn920, PMID: 12209121

Berkefeld H, Sailer CA, Bildl W, Rohde V, Thumfart JO, Eble S, Klugbauer N, Reisinger E, Bischofberger J, Oliver D, Knaus HG, Schulte U, Fakler B. 2006. BKCa-Cav channel complexes mediate rapid and localized Ca2+-activated K+ signaling. Science 314:615–620. DOI: https://doi.org/10.1126/science.1132915, PMID: 17068255

Blaesse P, Airaksinen MS, Rivera C, Kaila K. 2009. Cation-chloride cotransporters and neuronal function. Neuron 61:820–838. DOI: https://doi.org/10.1016/j.neuron.2009.03.003, PMID: 19323993

Blaesse P, Guellimiot L, Schindler J, Schweizer M, Delpropiere F, Krichina A, Froemel J, Nothwang HG. 2006. The Journal of Neuroscience 26:10407–10419. DOI: https://doi.org/10.1523/JNEUROSCI.3257-06.2006, PMID: 17035525

Blaesse P, Schmidt T. 2015. K-Cl cotransporter KCC2—a moonlighting protein in excitatory and inhibitory synapse development and function. Pflügers Archiv - European Journal of Physiology 467:615–624. DOI: https://doi.org/10.1007/s00424-014-1547-6, PMID: 24909111

Brown KR, Jurisica I. 2007. Unequal evolutionary conservation of human protein interactions in interologous networks. Genome Biology 8:R95. DOI: https://doi.org/10.1186/gb-2007-8-5-r95, PMID: 17535438

Carroll RC, Beattie EC, Xia H, Lüscher C, Altschuler Y, Nicoll RA, Malenka RC, von Zastrow M. 1999. Dynamin-dependent endocytosis of ionotropic glutamate receptors. PNAS 96:14112–14117. DOI: https://doi.org/10.1073/pnas.96.24.14112, PMID: 10570207

Celnik G, Cherubini E. 2014. GABAergic signaling as therapeutic target for autism spectrum disorders. Frontiers in Pediatrics 2:70. DOI: https://doi.org/10.3389/fped.2014.00070, PMID: 25072038

Cembrowski MS, Wang L, Sugino K, Shields BC, Spruston N. 2016. Hipposeq: a comprehensive RNA-seq database of gene expression in hippocampal principal neurons. eLife 5:e14997. DOI: https://doi.org/10.7554/eLife.14997, PMID: 27113915
Chamma I, Chevy Q, Poncer JC, Lévi S. 2012. Role of the neuronal K-Cl co-transporter KCC2 in inhibitory and excitatory neurotransmission. Frontiers in Cellular Neuroscience 6:5. DOI: https://doi.org/10.3389/fncel.2012.00005, PMID: 22363264

Chamma I, Heubl M, Chevy Q, Renner M, Moutkine I, Eugène E, Poncer JC, Lévi S. 2013. Activity-dependent regulation of the K/Cl transporter KCC2 membrane diffusion, clustering, and function in hippocampal neurons. Journal of Neuroscience 33:15488–15503. DOI: https://doi.org/10.1523/JNEUROSCI.5889-12.2013, PMID: 24068817

Chevy Q, Heubl M, Goutierrez M, Backer S, Moutkine I, Eugène E, Bloch-Gallego E, Lévi S, Poncer JC. 2015. KCC2 gates activity-driven ampa receptor traffic through coflin phosphorylation. Journal of Neuroscience 35:15772–15786. DOI: https://doi.org/10.1523/JNEUROSCI.1735-15.2015, PMID: 26631461

Chiu CQ, Lur G, Morse TM, Carnevale NT, Ellis-Davies GC, Higley MJ. 2013. Compartmentalization of GABAergic inhibition by dendritic spines. Science 340:759–762. DOI: https://doi.org/10.1126/science.1234274, PMID: 23661763

Choi H, Liu G, Mellacheruvu D, Tyers M, Gingras AC, Nesiwzhik Al. 2012. Analyzing protein-protein interactions from affinity purification-mass spectrometry data with SAINT. Current Protocols in Bioinformatics Chapter 8: Unlit8.15. DOI: https://doi.org/10.1002/0471250953.bi0815s39

Clayton EL, Anggonovo V, Smillie KJ, Chau N, Robinson PJ, Cousin MA. 2009. The phospho-dependent dynamin-syndapin interaction triggers activity-dependent bulk endocytosis of synaptic vesicles. Journal of Neuroscience 29:7706–7717. DOI: https://doi.org/10.1523/JNEUROSCI.1735-15.2015, PMID: 24068817

Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross D, Hae.S, Isserlin R, Kelley R, Kilcoyne S, Lotia M, Maere S, Morris J, Ono K, Pavlovic V, Pico AR, et al. 2007. Integration of biological networks and gene expression data using Cytoscape. Nature Protocols 2:2366–2382. DOI: https://doi.org/10.1038/nprot.2007.324, PMID: 17947979

Collins MO, Husi H, Yu L, Brandon JM, Anderson CN, Blackstock WP, Choudhary JS, Grant SG. 2006. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. Journal of Neuroscience 97:16–23. DOI: https://doi.org/10.1111/j.1471-4159.2005.03507.x, PMID: 16635246

Comstera HS, Marthy J, Rudin-Rush S, Hartwig C, Gokhale A, Zlatic SA, Blackburn JB, Werner E, Petris M, D’Souza P, Panuwet P, Barr DB, Lupashin V, Faundez V. 2017. The interactome of the copper transporter ATP7A belongs to a network of neurodevelopmental and neurodegeneration factors. eLife 6:e24772. DOI: https://doi.org/10.7554/eLife.24772, PMID: 28355134

Coulja JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y, a PS, De Koninck Y. 2003. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 424:938–942. DOI: https://doi.org/10.1038/nature01868, PMID: 12931188

Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. 2011. Andromeda: a peptide search engine integrated into the MaxQuant environment. Journal of Proteome Research 10:1799–1805. DOI: https://doi.org/10.1021/pr101065j, PMID: 21254760

Craig R, Beavis RC. 2004. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 20:1466–1467. DOI: https://doi.org/10.1093/bioinformatics/bth092, PMID: 14976030

César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, Superti-Furga G. 2015a. A call for systematic research on solute carriers. Cell 162:478–487. DOI: https://doi.org/10.1016/j.cell.2015.07.022

César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, Superti-Furga G. 2015b. A call for systematic research on solute carriers. Cell 162:478–487. DOI: https://doi.org/10.1016/j.cell.2015.07.022, PMID: 26232220

Del Pino I, Koch D, Schemm R, Qualmann B, Betz H, Paarmann I. 2014. Proteomic analysis of glyceroldehyde 3-phosphate dehydrogenase (GLYDH)-interacting proteins: evidence for synapdin I regulating synaptic glyceroldehyde 3-phosphate dehydrogenase. The Journal of biological chemistry 289:11396–11409. DOI: https://doi.org/10.1074/jbc.M113.504860, PMID: 24509844

Diamant BJ, Noble WS. 2011. Faster SEQUEST searching for peptide identification from tandem mass spectra. Journal of Proteome Research 10:3871–3879. DOI: https://doi.org/10.1021/pr101196n, PMID: 21761931

Dorfer V, Pichler P, Stranzl T, Stadtmann J, Taus T, Winkler S, Mechtler K. 2014. MS Amanda, a universal identification algorithm optimized for high accuracy tandem mass spectra. Journal of Proteome Research 13:3679–3684. DOI: https://doi.org/10.1021/pr5002026, PMID: 24909410

Doyon N, Vinay L, Prescott SA, De Koninck Y. 2016. Chloride regulation: a dynamic equilibrium crucial for synaptic inhibition. Neuron 89:1157–1172. DOI: https://doi.org/10.1016/j.neuron.2016.02.030, PMID: 26985723

Elias JE, Gygi SP. 2010. Target-decoy search strategy for mass spectrometry-based proteomics. Methods in molecular biology 604:55–71. DOI: https://doi.org/10.1007/978-1-60761-444-9_5, PMID: 20013364

Eng JK, Jahan TA, Hoopmann MR. 2013. Comet: an open-source MS/MS sequence database search tool. Proteomics 13:22–24. DOI: https://doi.org/10.1002/pmic.201002439, PMID: 23148064

Farr CD, Galken PR, Norbeck AD, Doneanu CE, Stapels MD, Barošky DF, Minami M, Saugstad JA, a SJ. 2004. Proteomic analysis of native metabotropic glutamate receptor 5 protein complexes reveals novel molecular constituents. Journal of Neurochemistry 91:438–450. DOI: https://doi.org/10.1111/j.1471-4159.2004.02735.x, PMID: 15447677

Fiumelli H, Briner A, Puskarjov M, Blaesse P, Belem BJ, Dayer AG, Kaila K, Martin JL, Vutskits L. 2013. An ion transport-independent role for the cation-chloride cotransporter KCC2 in dendritic spineogenesis in vivo. Cerebral Cortex 23:378–388. DOI: https://doi.org/10.1093/cercor/bhs027, PMID: 22345354

Ford A, Castonguay A, Cottet M, Little JW, Chen Z, Synoms-Liguori AM, Doyle T, Egan TM, Vanderah TW, De Koninck Y, Tosh DK, Jacobson KA, Salvemini D. 2015. Engagement of the GABA to KCC2 signaling pathway...
contributes to the analgesic effects of A3AR agonists in neuropathic pain. *Journal of Neuroscience* **35**:6057–6067. DOI: https://doi.org/10.1523/JNEUROSCI.4495-14.2015, PMID: 25878279

Friedel P, Kahle KT, Zhang J, Hertz N, Pisiella Li, Buhler E, Schaller F, Duan J, Khanna AR, Bishop PN, Shokat KM, Medina I. 2015. WNK1-regulated inhibitory phosphorylation of the KCC2 cotransporter maintains the depolarizing action of GABA in immature neurons. *Science Signaling* **8**:ra65. DOI: https://doi.org/10.1126/scisignal.aaa0354, PMID: 26126716

Garbarini N, Deliere E. 2008. The RCC1 domain of protein associated with Myc (PAM) interacts with and regulates KCC2. *Cellular Physiology and Biochemistry* **22**:031–044. DOI: https://doi.org/10.1159/000149781, PMID: 18769030

Gauvain G, Chamma I, Chevy Q, Cabezas C, Irinopoulou T, Bodrug N, Carmaud M, Lévi S, Poncer JC. 2011. The neuronal K-Cl cotransporter KCC2 influences postsynaptic AMPA receptor content and lateral diffusion in dendritic spines. *PNAS* **108**:15474–15479. DOI: https://doi.org/10.1073/pnas.1107893108, PMID: 21878564

Geer LY, Markey SP, Kowalak JA, Wagner L, Xu M, Maynard DM, Yang X, Shi W, Bryant SH. 2004. Open mass spectrometry search algorithm. *Journal of Proteome Research* **3**:958–964. DOI: https://doi.org/10.1021/pr4039491, PMID: 15473683

Gulyás AI, Sik A, Payne JA, Kaila K, Freund TF, Gulya AI. 2001. The KCl cotransporter, KCC2, is highly expressed in the vicinity of excitatory synapses in the rat hippocampus. *European Journal of Neuroscience* **13**:2205–2217. DOI: https://doi.org/10.1046/j.0953-816x.2001.01600.x, PMID: 11454023

Haase J, Grudzinska-Goebel J, Müller HK, Münster-Wandowski A, Chow E, Wynne K, Farsi Z, Zander JF, Ahnert-Hilger G. 2017. Serotonin Transporter associated protein complexes are enriched in synaptic vesicle proteins and proteins involved in energy metabolism and ion homeostasis. *ACS Chemical Neuroscience* **8**:1110–1116. DOI: https://doi.org/10.1021/acschemneuro.6b00437, PMID: 28362488

Heller EA, Zhang W, Selimi F, Earnheart JC, Śliłmak MA, Santos-Torres J, Ibañez-Tallon I, Aoki C, Chait BT, Heintz N. 2012. The biochemical anatomy of cortical inhibitory synapses. *PLoS One* **7**:e39572. DOI: https://doi.org/10.1371/journal.pone.0039572, PMID: 22768092

Higley MJ. 2014. Localized GABAergic inhibition of dendritic Ca(2+) signalling. *Nature Reviews Neuroscience* **15**:567–572. DOI: https://doi.org/10.1038/nrn3803, PMID: 21516141

Horn Z, Ringstedt T, Blaesse P, Kaila K, Herlenius E. 2010. Premature expression of KCC2 in embryonic mice perturbs neural development by an ion transport-independent mechanism. *European Journal of Neuroscience* **31**:2142–2155. DOI: https://doi.org/10.1111/j.1460-9568.2010.07258.x, PMID: 20529123

Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R, Rivera C. 2007. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. *Journal of Neuroscience* **27**:9866–9873. DOI: https://doi.org/10.1523/JNEUROSCI.2761-07.2007, PMID: 17855601

Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. 2000. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. *Nature neuroscience* **3**:661–669. DOI: https://doi.org/10.1038/76615, PMID: 10862698

Ikeda K, Onimaru H, Yamada J, Inoue K, Ueno S, Onaka T, Toyoda H, Arata A, Ishikawa TO, Taketo MM, Fukuda A, Kawakami K. 2004. Malfuction of respiratory-related neuronal activity in Na+, K+-ATPase alpha2 subunit-deficient mice is attributable to abnormal Cl- homeostasis in brainstem neurons. *Journal of Neuroscience* **24**:10693–10701. DOI: https://doi.org/10.1523/JNEUROSCI.2909-04.2004, PMID: 15564586

Inoue K, Ueno S, Fukuda A. 2004. Interaction of neuron-specific K+-Cl- cotransporter, KCC2, with brain-type creatine kinase. *FEBS Letters* **564**:131–135. DOI: https://doi.org/10.1016/S0014-5793(04)00328-X, PMID: 15094054

Inoue K, Yamada J, Ueno S, Fukuda A. 2006. Brain-type creatine kinase activates neuron-specific K+-Cl- cotransporter KCC2. *Journal of Neuroscience* **96**:598–608. DOI: https://doi.org/10.1101/j.1471-4159.2005.03560.x, PMID: 16356223

Ivakine EA, Acton BA, Mahadevan V, Ormond J, Tang M, Pressey JC, Huang MY, Ng D, Deliere E, Salter MW, Woodin MA, McNees RR. 2013. Neto2 is a KCC2 interacting protein required for neuronal Cl- regulation in hippocampal neurons. *PNAS* **110**:3561–3566. DOI: https://doi.org/10.1073/pnas.1219207110, PMID: 23401525

Kahle KT, Deeb TZ, Puskarjov M, Silayeva L, Liang B, Kaila K, Moss SJ. 2013. Modulation of neuronal activity by phosphorylation of the K-Cl cotransporter KCC2. *Trends in Neurosciences* **36**:726–737. DOI: https://doi.org/10.1016/tins.2013.08.006, PMID: 24139641

Kahle KT, Merned ND, Friedel P, Silayeva L, Liang B, Khanna A, Shang Y, Lachance-Touchette P, Bourassa C, Levert A, Dion PA, Walcott B, Spiegelman D, Dione-Laporte A, Hodgkinson A, Awadalla P, Nikbakht H, Majewski J, Cossette P, Deeb TZ, et al. 2014. Genetically encoded impairment of neuronal KCC2 cotransporters in neurological disease. *Nature Clinical Practice Neurology* **4**:598–608. DOI: https://doi.org/10.1038/ncpneuro0883, PMID: 18769373

Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. 2014. Cation-clloride cotransporters in neuronal development, plasticity and disease. *Nature Reviews Neuroscience* **15**:637–654. DOI: https://doi.org/10.1038/nrn3819, PMID: 25234263

Kaila K. 1994. Ionic basis of GABAAR receptor channel function in the nervous system. *Progress in Neurobiology* **42**:489–537. DOI: https://doi.org/10.1016/0301-0082(94)90049-3, PMID: 75223344

Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, Sousa AM, Pletikos M, Meyer KA, Sedmak G, Guennel T, Shin Y, Johnson MB, Krsnik Z, Mayer S, Furtzinhos S, Umlauf S, Lisgo SN, Vortmeyer A, Weinberger DR, et al.
2011. Spatio-temporal transcriptome of the human brain. Nature 478:483–489. DOI: https://doi.org/10.1038/nature10523, PMID: 22031440

Kang Y, Ge Y, Cassidy RM, Lam V, Luo L, Moon KM, Lewis R, Molday RS, Wong RO, Foster LJ, Craig AM. 2014. A combined transgenic proteomic analysis and regulated trafficking of neurologin-2. Journal of Biological Chemistry 289:29350–29364. DOI: https://doi.org/10.1074/jbc.M114.549279, PMID: 25190809

Keller A, Nesvizhskii AI, Kolker E, Aebersold R. 2002. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Analytical Chemistry 74:5383–5392. DOI: https://doi.org/10.1021/ac025747h, PMID: 12403597

Kessels MM, Qualmann B. 2004. The syndapin protein family: linking membrane trafficking with the cytoskeleton. Journal of Cell Science 117:3077–3086. DOI: https://doi.org/10.1242/jcs.01290, PMID: 15226389

Kessels MM, Qualmann B. 2006. Syndapin oligomers interconnect the machineries for endocytic vesicle formation and actin polymerization. Journal of Biological Chemistry 281:13285–13299. DOI: https://doi.org/10.1074/jbc.M510226200, PMID: 16540475

Kessels MM, Qualmann B. 2015. Different functional modes of BAR domain proteins in formation and plasticity of mammalian postsynapses. Journal of Cell Science 128:3177–3185. DOI: https://doi.org/10.1242/jcs.174193, PMID: 26285709

Kim S, Pevzner PA. 2014. MS-GF+ makes progress towards a universal database search tool for proteomics. Nature Communications 5:5277. DOI: https://doi.org/10.1038/ncomms6277, PMID: 25358478

Kotlyar M, Pastrello C, Pivetta F, Lo Sardo A, Cumbaa C, Li H, Naranian T, Niu Y, Ding Z, Vafaee F, Broackes-Carter F, Petschnigg J, Mills GB, Jurisica I, Maestro R, Jurisica I. 2015. In silico prediction of physical protein interactions and characterization of interactome orphans. Nature Methods 12:79–84. DOI: https://doi.org/10.1038/nmeth.3178, PMID: 25402006

Kyrozos A, Reichling DB. 1995. Perforated-patch recording with gramicidin avoids artifactual changes in intracellular chloride concentration. Journal of Neuroscience Methods 57:27–35. DOI: https://doi.org/10.1016/0165-0270(94)00116-X, PMID: 7540702

Lee HH, Deeb TZ, Walker JA, Davies PA, Moss SJ. 2011. NMDA receptor activity downregulates KCC2 resulting in depolarizing GABA-mediated currents. Nature Neuroscience 14:736–743. DOI: https://doi.org/10.1038/nn.2806, PMID: 21532577

Lee HH, Walker JA, Williams JR, Goodier RJ, Payne JA, Moss SJ. 2007. Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2. Journal of Biological Chemistry 282:29777–29784. DOI: https://doi.org/10.1074/jbc.M705053200, PMID: 17693402

Lee SH, Liu L, Wang YT, Sheng M. 2002. Clathrin adaptor AP2 and NSF interact with overlapping sites of GluR2 and play distinct roles in AMPA receptor trafficking and hippocampal LTD. Neuron 36:661–674. DOI: https://doi.org/10.1016/S0896-6273(02)01024-3, PMID: 12441055

Leonzino M, Busnell M, Antonucci F, Verderio C, Mazzanti M, Chini B. 2016. The Timing of the excitatory-to-inhibitory gaba switch is regulated by the oxytocin receptor via KCC2. Cell Reports 15:96–103. DOI: https://doi.org/10.1016/j.celrep.2016.03.013, PMID: 27052180

Li H, Khiroug S, Cai C, Ludwig A, Blaesse P, Koliikova J, Afzalov R, Coleman SK, Lauri S, Airaksinen MS, Keinänen K, Khiroug L, Saarma M, Kaila K, Rivera C. 2007. KCC2 interacts with the dendritic cytoskeleton to promote spine development. Nature 56:1019–1033. DOI: https://doi.org/10.1038/j.neuron.2007.10.039, PMID: 18093524

Lin L, Yee SW, Kim RB, Giacomini KM. 2015. SLC transporters as therapeutic targets: emerging opportunities. Nature Reviews Drug Discovery 14:543–560. DOI: https://doi.org/10.1038/nrd4626, PMID: 26117766

Llano O, Smirnov S, Soni S, Golubtsov A, Guillemin I, Hotulainen P, Medina I, Nothwang HG, Rivera C, Ludwig A. 2015. KCC2 regulates actin dynamics in dendritic spines via interaction with β-PIX. The Journal of Cell Biology 209:671–686. DOI: https://doi.org/10.1083/jcb.201410006, PMID: 26051638

Loh KH, Stawski PS, Draycott AS, Udeshi ND, Lehrman EK, Wilton DK, Svinkina T, Deeb TZ, Walker JA, Davies PA, Ting AY. 2016. Proteomic analysis of unbounded cellular compartments: synaptic clefts. Cell 166:1295–1307. DOI: https://doi.org/10.1016/j.cell.2016.07.041, PMID: 27665350

Mahadevan V, Dargaei Z, Ivakine EA, Hartmann AM, Ng D, Chevrier J, Ormond J, Nothwang HG, McInnes RR, Woodin MA. 2015. Neto2-null mice have impaired GABAergic inhibition and are susceptible to seizures. Frontiers in Cellular Neuroscience 9:368. DOI: https://doi.org/10.3389/fncel.2015.00368, PMID: 26441539

Mahadevan V, Pressey JC, Acton BA, Uvarov P, Huang MY, Chevrier J, Puchalski A, Li CM, Ivakine EA, McInnes RR, Woodin MA. 2014. Kainate receptors coexist in a functional complex with KCC2 and regulate chloride homeostasis in hippocampal neurons. Cell Reports 7:1762–1770. DOI: https://doi.org/10.1016/j.celrep.2014.05.022, PMID: 24910435

Mahadevan V, Woodin MA. 2016. Regulation of neuronal chloride homeostasis by neuromodulators. The Journal of Neuroscience 36:2593–2605. DOI: https://doi.org/10.1111/jnp.12753, PMID: 26876607

Markkanen M, Karhunen T, Llano O, Ludwig A, Rivera C, Uvarov P, Airaksinen MS. 2014. Distribution of neuronal KCC2a and KCC2b isoforms in mouse CNS. Journal of Comparative Neurology 522:1897–1914. DOI: https://doi.org/10.1002/cne.23510, PMID: 24639001

Martens L, Hermjakob H, Jones P, Adamski M, Taylor C, States D, Gevaert K, Vandekeerckhove J, Apweiler R. 2005. PRIDE: the proteomics identifications database. Proteomics 5:3537–3545. DOI: https://doi.org/10.1002/pmic.200401303, PMID: 16041671
Medina I, Friedel P, Rivera C, Kahle KT, Kourdougli N, Uvarov P, Pellegrino C. 2014. Current view on the functional regulation of the neuronal K(+)−Cl(−) cotransporter KCC2. Frontiers in Cellular Neuroscience 8:27. DOI: https://doi.org/10.3389/fncel.2014.00027, PMID: 24567703

Mellacheruvu D, Wright Z, Couzens AL, Lambert JP, St-Denis NA, Li T, Miteva YV, Hauri S, Sardiu ME, Low TY, Halim VA, Bagshaw RD, Hubner NC, Al-Hakim A, Bouchard A, Faubert D, Fermin D, Dunham WH, Goudreault M, Lin ZY, et al. 2013. The CRAPome: a contaminant repository for affinity purification−mass spectrometry data. Nature Methods 10:730−736. DOI: https://doi.org/10.1038/nmeth.2557, PMID: 23921808

Modregger J, Ritter B, Witter B, Paulsson M, Plomann M. 2000. All three PACSIN isoforms bind to endocytic proteins and inhibit endocytosis. Journal of Cell Science 113:4511−4521. PMID: 11082044

Müller CS, Haupt A, Bildi W, Schindler J, Knaus HG, Meissner M, Rammner B, Striessnig J, Flockerzi V, Falkier B, Schulte U. 2010. Quantitative proteomics of the Cav2 channel nano-environments in the mammalian brain. PNAS 107:14950−14957. DOI: https://doi.org/10.1073/pnas.1005940107, PMID: 20668236

Nakamura Y, Morrow DH, Modgill A, Huyghe D, Deeb TZ, Lumb MJ, Davies PA, Moss SJ. 2016. Proteomic characterization of inhibitory synapses using a novel phluorin-tagged γ-amino butyric acid type a receptor, type a (gabaA), u2 subunit knock-in mouse. Journal of Biological Chemistry 291:12394−12407. DOI: https://doi.org/10.1074/jbc.M116.724443, PMID: 27044742

Nelson SB, Valakh V. 2015. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron 87:684−698. DOI: https://doi.org/10.1016/j.neuron.2015.07.033, PMID: 26291155

Nesvizhskii AI, Aeberold R. 2005. Interpretation of shotgun proteomic data: the protein inference problem. Molecular & cellular proteomics : MCP 4:1419−1440. DOI: https://doi.org/10.1074/mcp.M500012-MCP200, PMID: 16009968

Nesvizhskii AI, Keller A, Kolker E, Aeberold R. 2003. A statistical model for identifying proteins by tandem mass spectrometry. Analytical Chemistry 75:4646−4658. DOI: https://doi.org/10.1021/ac0341261, PMID: 14632076

Notartomaso S, Mascio G, Scarselli P, Martellino K, Fucile S, Gradini R, Bruno V, Battaglia G, Nicoletti F. 2017. Expression of the K(+)−Cl(−) cotransporter, KCC2, in cerebellar Purkinje cells is regulated by group-I metabotropic glutamate receptors. Neuropsychopharmacology 115:51−59. DOI: https://doi.org/10.1016/j.neuropsychopharmacology.2016.07.032, PMID: 27498071

Payne JA, Stevenson TJ, Donaldson LF. 1996. Molecular characterization of a putative K-Cl cotransporter in rat brain. A neuronal-specific isoform. The Journal of Biological Chemistry 271:16245−16252. PMID: 8663311

Pin JP, Betterl B. 2016. Organization and functions of mGlu and GABAB receptor complexes. Nature 540:60−68. DOI: https://doi.org/10.1038/nature21056, PMID: 27905440

Powell DW, Weaver CM, Jennings JL, McAfee KJ, He Y, Weil PA, Link AJ. 2004. Cluster analysis of mass spectrometry data reveals a novel component of SAGA. Molecular and Cellular Biology 24:7249−7259. DOI: https://doi.org/10.1128/MCB.24.16.7249-7259.2004, PMID: 15282323

Pressey JC, Mahadevan V, Khademullah CS, Dargaei Z, Chevrier J, Ye W, Huang M, Chauhan AK, Meis J, Uvarov P, Airaksinen MS, Woodin MA. 2017. A kainate receptor subunit promotes the recycling of the neuronal-specific K(+)−Cl(−) co-transporter KCC2 in hippocampal neurons. Journal of Biological Chemistry 292:6190−6201. DOI: https://doi.org/10.1074/jbc.M116.767236, PMID: 28235805

Puskarjov M, Ahmad F, Kaila K, Blass P. 2012. Activity-dependent cleavage of the K-Cl cotransporter KCC2 mediated by calcium-activated protease calpain. Journal of Neuroscience 32:11356−11364. DOI: https://doi.org/10.1523/JNEUROSCI.6265-11.2012, PMID: 22895718

Puskarjov M, Seja P, Heron SE, Williams TC, Ahmad F, Iona X, Oliver KL, Grinton BE, Vutsikits L, Scheffer IE, Petrou S, Blass P, Dibbens LM, Berkovic SF, Bavorova K. 2014. A variant of KCC2 in patients with febrile seizures impaired neuronal Cl− extrusion and dendritic spine formation. EMBO reports 15:1−7. DOI: https://doi.org/10.15252/embr.201438749, PMID: 24662662

Pérez-Otaño I, Luján R, Taválin SJ, Plomann M, Modregger J, Liu XB, Jones EG, Heinemann SF, Lo DC, Ehlers MD. 2006. Endocytosis and synaptic removal of NR3A-containing NMDA receptors by PACSIN1/syndapin1. Nature Neuroscience 9:611−621. DOI: https://doi.org/10.1038/nn1680, PMID: 16617342

Ramachandran N, Munteanu I, Wang P, Ruggieri A, Rilstone JJ, Israeli N, Nararian T, Paroutis P, Guo R, Ren ZP, Nishino I, Chabrol B, Pellissier JP, Minetti C, Udd B, Fardeau M, Tailor CS, Mahuran DJ, Kissel JT, Calimo H, et al. 2013. VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy. Acta Neuropathologica 125:439−457. DOI: https://doi.org/10.1007/s00401-012-1073-6, PMID: 23310526

Rivela C, Voipio J, Payne JA, Ruisuvuo E, Lahtinen H, Lamasa K, Pirvola U, Saarma M, Kaila K. 1999. The K+/Cl− co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 397:251−255. DOI: https://doi.org/10.1038/16697, PMID: 9930699

Romero F. 2009. Solubilization and partial characterization of ouabain-insensitive Na+(+)/ATPase from basolateral plasma membranes of the intestinal epithelial cells. Investigacion clinica 50:303−314. PMID: 19961053

Roussa E, Speer JM, Chudotvorova I, Khakipoor S, Smirnov S, Rivera C, Kriegstein K. 2016. The membrane trafficking and functionality of the K+/Cl− co-transporter KCC2 is regulated by TGF-β2. Journal of Cell Science 129:3485−3498. DOI: https://doi.org/10.1242/jcs.189860, PMID: 27505893

Saito H, Watanabe M, Akita T, Ohba C, Sugai K, Ong WP, Shiraishi H, Yuasa S, Matsumoto H, Beng KT, Saitoh S, Miyatake S, Nakashima M, Miyake N, Kato M, Fukuda A, Matsumoto N. 2016. Impaired neuronal KCC2 function by biallelic SLC12A5 mutations in migrating focal seizures and severe developmental delay. Scientific Reports 6:30072. DOI: https://doi.org/10.1038/srep30072, PMID: 27426767

Sanz-Clemente A, Matta JA, Isaac JT, Roche KW. 2010. Casein kinase 2 regulates the NR2 subunit composition of synaptic NMDA receptors. Neuron 67:984−996. DOI: https://doi.org/10.1016/j.neuron.2010.08.011, PMID: 20869595
Sarkar J, Wakefield S, MacKenzie G, Moss SJ, Maguire J. 2011. Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors. Journal of Neuroscience 31: 18198–18210. DOI: https://doi.org/10.1523/JNEUROSCI.2560-11.2011, PMID: 22171026

Schulte U, Müller CS, Falkier B. 2011. Ion channels and their molecular environments—glimpses and insights from functional proteomics. Seminars in Cell & Developmental Biology 22: 132–144. DOI: https://doi.org/10.1016/j. semcdsb.2010.09.015, PMID: 20934526

Schwenk J, Baehrens D, Haupert A, Bliedt W, Bouddkazi S, Roeppe J, Falkier B, Schulte U. 2014. Regional diversity and developmental dynamics of the AMPA-receptor proteome in the mammalian brain. Neuron 84: 41–54. DOI: https://doi.org/10.1016/j.neuron.2014.08.044, PMID: 25422241

Schwenk J, Harmel N, Brechet A, Zolles G, Berkelfeld H, Müller CS, Bliedt W, Baehrens D, Huber B, Kulk J, Klöcker N, Schulte U, Falkier B. 2012. High-resolution proteomics unravels architecture and molecular diversity of native AMPA receptor complexes. Neuron 74: 621–633. DOI: https://doi.org/10.1016/j.neuron.2012.03.034, PMID: 22632720

Schwenk J, Metz M, Zolles G, Turecek R, Fritzius T, Bliedt W, Tarusawa E, Kulk J, Unger A, Ivankova K, Seditk R, Tiao JY, Rajalu M, Trojanova J, Rohde V, Gassmann M, Schulte U, Falkier B, Bettler B. 2010. Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits. Nature 465: 235–239. DOI: https://doi.org/10.1038/nature08964, PMID: 20409944

Schwenk J, Pérez-Garcí E, Schneider A, Kollewe A, Gauthier-Kemper A, Fritzius T, Raveh A, Dinaamraca MC, Hanuschkin A, Bliedt W, Klingauf J, Gassmann M, Schulte U, Bettler B. 2016. Modular composition and dynamics of native GABAB receptors identified by high-resolution proteomics. Nature Neuroscience 19: 233–242. DOI: http://dx.doi.org/10.1038/nn.4198, PMID: 26691831

Selak S, Paternain AV, Aller MI, Aller JM, Picó E, Rivera R, Lemna J. 2009. A role for SNAP25 in internalization of kainate receptors and synaptic plasticity. Neuron 63: 357–371. DOI: https://doi.org/10.1016/j.neuron.2009.07.017, PMID: 19679075

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research 13: 2498–2504. DOI: https://doi.org/10.1101/gr.1239303, PMID: 14597658

Silayeva L, Deeb TZ, Hines RM, Kelley MR, Munoz MB, Lee HH, Brandon NJ, Dunlop J, Maguire J, Davies PA, Moss SJ. 2015. KCC2 activity is critical in limiting the onset and severity of status epilepticus. PNAS 112: 3523–3528. DOI: https://doi.org/10.1073/pnas.1415126112, PMID: 25733865

Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. 2006. BioGRID: a general repository for interaction datasets. Nucleic Acids Research 34:D535–D539. DOI: https://doi.org/10.1093/nar/gkj109, PMID: 16381927

Stödberg T, McGctte A, Ruiz AJ, Hirata H, Zhn J, Long P, Farabella I, Meyer E, Kawahara A, Vassallo G, Stivaros SM, Bjursell MK, Stranneheim H, Tigerschöld S, Persson B, Bangash I, Das K, Hughes D, Lesko N, Lundeberg J, et al. 2015. Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nature Communications 6: 8038. DOI: https://doi.org/10.1038/ncomms9038, PMID: 26333769

Swamy M, Siegers GM, Minguet S, Wollscheid B, Schamel WW. 2006. Blue native polyacrylamide gel electrophoresis (BN-PAGE) for the identification and analysis of multiprotein complexes. Science Signaling 2006: pl4. DOI: https://doi.org/10.1126/sci信号.3452006p1, PMID: 16863805

Tabb DL, Fernando CG, Chambers MC. 2007. MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. Journal of Proteome Research 6: 654–661. DOI: https://doi.org/10.1021/pr0604054, PMID: 17269722

Tang X, Kim J, Zhou L, Wengert E, Zhang L, Wu Z, Carromeu C, Muotri AR, Marchetto MC, Gage FH, Chen G. 2016b. KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome. PNAS 113: 751–756. DOI: https://doi.org/10.1073/pnas.1524013113, PMID: 26733678

Tang X, Kim J, Zhou L, Wengert E, Zhang L, Wu Z, Carromeu C, Muotri AR, Marchetto MCN, Gage FH, Chen G. 2016a. KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome. PNAS 113: 751–756. DOI: https://doi.org/10.1073/pnas.1415126112, PMID: 25733865

Tao R, Li C, Newburn EN, Ye T, Lipska BK, Herman MM, Weinberger DR, Kleinman JE, Hyde TM. 2012. Transcription-specific associations of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective disorders. Journal of Neuroscience 32: 5216–5222. DOI: https://doi.org/10.1523/JNEUROSCI.4626-11.2012, PMID: 22496567

Toda T, Ishida K, Kiyama H, Yamashita T, Lee S. 2014. Down-regulation of KCC2 expression and phosphorylation in motoneurons, and increases the number of primary afferent projections to motoneurons in mice with post-stroke spasticity. PLoS One 9: e114328. DOI: https://doi.org/10.1371/journal.pone.0114328, PMID: 25546454

Uezu A, Kanak DJ, Bradshaw TW, Soderblom EJ, Catavero CM, Burette AC, Weinberg RJ, Soderling SH. 2016. Identification of an elaborate complex mediating postsynaptic inhibition. Science 353: 1123–1129. DOI: https://doi.org/10.1126/science.aag0821, PMID: 27609886

Uvarov P, Ludwig A, Markkanen M, Pruunsild P, Kaila K, Delpire E, Timmusk T, Rivera C, Airaksinen MS. 2007. A novel N-terminal isoform of the neuron-specific K-Cl cotransporter KCC2. Journal of Biological Chemistry 282: 30570–30576. DOI: https://doi.org/10.1074/jbc.M705092200, PMID: 17715129

Uvarov P, Ludwig A, Markkanen M, Soni S, Hübner CA, Rivera C, Airaksinen MS. 2009. Coexpression and heteromerization of two neuronal K-Cl cotransporters in the mammalian brain. Journal of Biological Chemistry 284: 13696–13704. DOI: https://doi.org/10.1074/jbc.M807366200, PMID: 19307176

Vandenberghe W, Nicoll RA, Brett DS. 2005. Stargazin is an AMPA receptor auxiliary subunit. PNAS 102: 485–490. DOI: https://doi.org/10.1073/pnas.0408269102, PMID: 15630087
Vaudel M, Barsnes H, Berven FS, Sickmann A, Martens L. 2011. SearchGUI: An open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. PROTEOMICS 11:996–999. DOI: https://doi.org/10.1002/pmic.201000595, PMID: 21337703

Vaudel M, Burkhardt JM, Zahedi RP, Oveland E, Berven FS, Sickmann A, Martens L, Barsnes H. 2015. PeptideShaker enables reanalysis of MS-derived proteomics data sets. Nature Biotechnology 33:22–24. DOI: https://doi.org/10.1038/nbt.3109, PMID: 25574629

Vizcaíno JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Ríos D, Dianes JA, Sun Z, Farrah T, Bandeira N, Binz PA, Xenarios I, Eisenacher M, Mayer G, Gatto L, Campos A, Chalkley RJ, Kraus HJ, Albar JP, Martinez-Bartolomé S, et al. 2014. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nature Biotechnology 32:223–226. DOI: https://doi.org/10.1038/nbt.2839, PMID: 24727771

Wake H, Watanabe M, Moorhouse AJ, Kanematsu T, Horibe S, Matsukawa N, Asai K, Ojika K, Hirata M, Nabekura J. 2007. Early changes in KCC2 phosphorylation in response to neuronal stress result in functional downregulation. Journal of Neuroscience 27:1642–1650. DOI: https://doi.org/10.1523/JNEUROSCI.3104-06.2007, PMID: 17301172

Watanabe M, Wake H, Moorhouse AJ, Nabekura J. 2009. Clustering of neuronal K+-Cl- cotransporters in lipid rafts by tyrosine phosphorylation. Journal of Biological Chemistry 284:27980–27988. DOI: https://doi.org/10.1074/jbc.M109.043620, PMID: 19679663

Wenz M, Hartmann AM, Friauf E, Nothwang HG. 2009. CIP1 is an activator of the K+-Cl- cotransporter KCC2. Biochemical and Biophysical Research Communications 381:388–392. DOI: https://doi.org/10.1016/j.bbrc.2009.02.057, PMID: 19232517

Widagdo J, Fang H, Jang SE, Anggono V. 2016. PACSIN1 regulates the dynamics of AMPA receptor trafficking. Scientific Reports 6:31070. DOI: https://doi.org/10.1038/srep31070, PMID: 27488904

Williams JR, Sharp JW, Kumari VG, Wilson M, Payne JA. 1999. The Neuron-specific K-Cl Cotransporter, KCC2. Journal of Biological Chemistry 274:12656–12664. DOI: https://doi.org/10.1074/jbc.274.18.12656

Willesey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, Reilly SK, Lin L, Fertuzinhos S, Miller JA, Murtha MT, Bichsel C, Niw N, Cotney J, Ercan-Sencicek AG, Gockley J, Gupta AR, Han W, He X, Hoffman EJ, et al. 2013. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 155:997–1007. DOI: https://doi.org/10.1016/j.cell.2013.10.020, PMID: 24267886

Woo NS, Lu J, England R, McClellan R, Dufour S, Mount DB, Deutch AY, Lovinger DM, Delpere E. 2002. Hyperexcitability and epilepsy associated with disruption of the mouse neuronal-specific K-Cl cotransporter gene. Hippocampus 12:258–268. DOI: https://doi.org/10.1002/hipo.10014, PMID: 12000122

Wright R, Newey SE, Ille A, Wefelmeyer W, Raimondo JV, Ginham R, McIlhinney RAJ, Akerman CJ. 2017. Neuronal Chloride Regulation via KCC2 Is Modulated through a GABAB Receptor Protein Complex. The Journal of Neuroscience 37:5447–5462. DOI: https://doi.org/10.1523/JNEUROSCI.2164-16.2017, PMID: 28450542

Mahadevan et al. eLife 2017;6:e28270. DOI: https://doi.org/10.7554/eLife.28270

34 of 34